hydroxyurea has been researched along with Granulocytic Leukemia, Chronic in 428 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Hydroxyurea-induced leg ulcer has been found in patients on long-term hydroxyurea therapy." | 8.02 | Chronic Myeloid Leukaemia with Sudden Bilateral Deafness and Leg Ulcer Associated with Hydroxyurea Therapy. ( Ibiam, FA; Nnachi, OA; Okoh, NU; Okoye, AE; Ugwu, CN; Ugwu, GC; Ugwu, NI, 2021) |
| " Hydroxyurea-induced dermatomyositis is a rare adverse reaction of long-term hydroxyurea therapy." | 7.78 | Hydroxyurea-induced dermatomyositis: true amyopathic dermatomyositis or dermatomyositis-like eruption? ( El-Din, ES; Nofal, A, 2012) |
| "Gangrene of the toes and digits appears to be a rare but very severe complication of long-term hydroxyurea therapy." | 7.71 | Gangrene of the toes in a patient with chronic myelogenous leukemia after long-term hydroxyurea therapy. ( Hehlmann, R; Ho, AD; Hochhaus, A; Krämer, A; Krasniqi, F; Leo, E, 2002) |
| "Hydroxyurea (HU) is usually a well-tolerated antineoplastic agent, which is commonly used in the treatment of myeloproliferative disorders." | 7.71 | [Hydroxyurea-induced leg ulcers in patients with chronic myeloproliferative disorders]. ( Olesen, LH; Pedersen, BB, 2001) |
| "A 51-year-old male who had intractable leg ulcers during treatment for chronic myelogenous leukaemia with hydroxyurea (HU) is reported." | 7.71 | Successful treatment for leg ulcers due to hydroxyurea in a patient with chronic myelogenous leukaemia. ( Kamada, T; Kawabata, H; Makino, T; Suzuki, S; Takatsuka, Y; Takeuchi, S; Utsunomiya, A, 2002) |
| "We report on dermatomyositis-like adverse cutaneous reactions following long-term maintenance therapy with hydroxyurea in two patients suffering from chronic myelogenous leukaemia (CML)." | 7.69 | [Dermatomyositis-like skin changes with long-term hydroxyurea (Litalir) therapy]. ( Merkel, M; Pillekamp, H; Schick, E; Sterry, W; Weber, L, 1995) |
| " We present an unusual Ph-positive CML case, which developed lymphoid blast crisis in complete cytogenetic remission following interferon-alpha and hydroxyurea therapy." | 7.69 | Lymphoid blast crisis during complete cytogenetic remission following interferon-alpha and hydroxyurea therapy. ( Bose, S; Chowdhry, VP; Kucheria, K; Saxena, R, 1997) |
| "The effect of hydroxyurea on blood viscosity was studied in 10 patients with Philadelphia chromosome positive chronic myelogenous leukemia (CML) and hyperleukocytosis (white blood cell counts over 200 x 10(9)/l)." | 7.68 | Effect of hydroxyurea on blood viscosity in chronic myelogenous leukemia with hyperleukocytosis. ( Bhat, SV; Rao, S; Sharma, K, 1991) |
| "The use of hydroxyurea in chronic myeloid leukemia during pregnancy is unknown." | 6.67 | Use of hydroxyurea in chronic myeloid leukemia during pregnancy: a case report. ( Dukes, IA; Hull, JC; Patel, M, 1991) |
| "Hydroxyurea is an antimetabolite that is widely used in the treatment of many benign and malignant conditions." | 5.42 | Hydroxyurea-induced oral ulceration. ( Almazrooa, S; Alsayes, F; Azher, F; Badawi, M, 2015) |
| "Hydroxyurea is an antineoplasic agent usually used in myeloproliferative syndromes, but also in other benign pathological circumstances." | 5.33 | [Leg ulcer due to hydroxyurea. A case report]. ( Debonne, JM; Diagne-Guèye, NM; Fall, F; Gning, SB; Mbaye, PS; Ndiaye, B, 2006) |
| "He had been diagnosed as having chronic myeloid leukemia in 1999, and since then, he had continued to take hydroxyurea (1500 mg/day) orally." | 5.32 | [Severe hyponatremia with consciousness disturbance caused by hydroxyurea in a patient with chronic myeloid leukemia]. ( Kurata, M; Maeda, A; Matsushita, A; Nagai, K; Takahashi, T; Tanaka, Y; Tani, M; Watanabe, N, 2004) |
| "We report a 45-year-old male with chronic myelogenous leukemia (CML) who experienced skin ulcers of the left lateral malleolus and dorsum of both feet." | 5.30 | [Bilateral leg ulcers with pathologic evidence of small vessel vasculitis by skin biopsy during hydroxyurea therapy of chronic myelogenous leukemia]. ( Irimajiri, J; Ito, T; Kanazawa, A; Kawahara, Y; Kudo, H; Ohkubo, H; Tomiyama, J; Uchino, S; Yano, K, 1997) |
| "A 59-year-old man with chronic myelogenous leukemia (CML) had a white-blood-cell (WBC) count of 55,400/microliter when admitted in July 1997, and was placed on oral hydroxyurea (HU) of 1,500 mg/day." | 5.30 | [Myositis caused by hydroxyurea in a patient with chronic myelogenous leukemia]. ( Ikeda, K; Ishibashi, T; Maruyama, Y; Mita, M; Shichishima, T, 1998) |
| "Hydroxyurea was continued for two more years and the lesions worsened." | 5.29 | [Multiple keratosis induced by hydroxyurea]. ( Audhuy, B; Couilliet, D; Grange, F; Guillaume, JC; Krzisch, S; Schlecht, P, 1995) |
| "Treatment of the myeloid blast phase of chronic granulocytic leukemia is still a major problem in clinical hematology." | 5.28 | Therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. ( Goudsmit, R; Ho, AD; Hunstein, W; Trümper, LH; van der Lelie, H, 1989) |
| "Monosomy 7 variant childhood chronic myelogenous leukemia (CML) is a rare, fatal leukemia that usually terminates in blast crisis." | 5.28 | Establishment of donor hematopoiesis after hydroxyurea-induced aplasia following allograft failure in a patient with monosomy 7 variant of childhood chronic myelogenous leukemia. ( Cassano, WF, 1989) |
| "Six patients with either acceleration or blast crisis of transformed chronic myeloid leukemia (CML) were treated with high-dose interferon alpha in combination with hydroxyurea." | 5.08 | Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon alpha and hydroxyurea: a novel approach. ( Heinemann, V; Jehn, U; Pötscher, C, 1995) |
| " Indirubin and meisoindigo induced hematologic remission in patients with chronic phase (CP) CML as effective as hydroxyurea and busulfan, in addition, there were no significant differences in median duration of CP, median survival and blast crisis at 60 months from diagnosis in indirubin, meisoindigo, hydroxyurea and busulfan treated groups." | 4.81 | Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. ( Hao, Y; Liu, B; Qian, L; Xiao, Z, 2002) |
| "A 48-year-old woman was admitted with chronic myelogenous leukemia in November, 1996 and was treated with hydroxyurea (HU), because of marked leukocytosis; WBC 404,000/microliter." | 4.80 | [Chronic myelogenous leukemia with long-term hypoplasia induced by alpha-interferon and hydroxyurea]. ( Fujimaki, K; Fujisawa, S; Hattori, M; Kodama, F; Maruta, A; Mohri, H; Motomura, S; Okubo, T; Sakai, R; Takahashi, N; Tomita, N, 1998) |
| " Hydroxyurea-induced leg ulcer has been found in patients on long-term hydroxyurea therapy." | 4.02 | Chronic Myeloid Leukaemia with Sudden Bilateral Deafness and Leg Ulcer Associated with Hydroxyurea Therapy. ( Ibiam, FA; Nnachi, OA; Okoh, NU; Okoye, AE; Ugwu, CN; Ugwu, GC; Ugwu, NI, 2021) |
| " Hydroxyurea-induced dermatomyositis is a rare adverse reaction of long-term hydroxyurea therapy." | 3.78 | Hydroxyurea-induced dermatomyositis: true amyopathic dermatomyositis or dermatomyositis-like eruption? ( El-Din, ES; Nofal, A, 2012) |
| "Hydroxyurea has replaced busulfan as first line treatment in CML since it prolongs survival." | 3.77 | Therapeutic progress and comparative aspects in chronic myelogenous leukemia (CML): interferon alpha vs. hydroxyurea vs. busulfan and expression of MMTV-related endogenous retroviral sequences in CML. German CML Study Group. ( Ansari, H; Hehlmann, R; Kister, P; Kolb, HJ; Papakonstantinou, G; Saussele, S; Schenk, M; Seifarth, W; Simon, M; Willer, A, 1994) |
| "We report three male patients, with duplex confirmed chronic venous disease, who were on treatment with hydroxyurea for chronic myelogenous leukaemia (CML) and polycythemia vera (PV), referred to us for the management of non-healing perimalleolar ulcers of varying durations." | 3.73 | Perimalleolar ulcers in hydroxyurea treated patients with concomitant chronic venous disease: diagnostic pitfalls. ( Gupta, K; Jain, V; Nagpal, N, 2005) |
| "A 77-year-old female with polycythemia vera (PV) showed a sudden, typical chronic myeloid leukaemia (CML), 8 yr after the initial diagnosis, and an intermittent treatment with hydroxyurea (0." | 3.73 | Transition of polycythemia vera to chronic myeloid leukaemia. ( Emilia, G; Ferrara, L; Fiorani, C; Longo, G; Mazzocchi, V; Saviola, A; Temperani, P; Torelli, G; Zucchini, P, 2005) |
| "Gangrene of the toes and digits appears to be a rare but very severe complication of long-term hydroxyurea therapy." | 3.71 | Gangrene of the toes in a patient with chronic myelogenous leukemia after long-term hydroxyurea therapy. ( Hehlmann, R; Ho, AD; Hochhaus, A; Krämer, A; Krasniqi, F; Leo, E, 2002) |
| "Hydroxyurea (HU) is usually a well-tolerated antineoplastic agent, which is commonly used in the treatment of myeloproliferative disorders." | 3.71 | [Hydroxyurea-induced leg ulcers in patients with chronic myeloproliferative disorders]. ( Olesen, LH; Pedersen, BB, 2001) |
| "A 51-year-old male who had intractable leg ulcers during treatment for chronic myelogenous leukaemia with hydroxyurea (HU) is reported." | 3.71 | Successful treatment for leg ulcers due to hydroxyurea in a patient with chronic myelogenous leukaemia. ( Kamada, T; Kawabata, H; Makino, T; Suzuki, S; Takatsuka, Y; Takeuchi, S; Utsunomiya, A, 2002) |
| "We report on dermatomyositis-like adverse cutaneous reactions following long-term maintenance therapy with hydroxyurea in two patients suffering from chronic myelogenous leukaemia (CML)." | 3.69 | [Dermatomyositis-like skin changes with long-term hydroxyurea (Litalir) therapy]. ( Merkel, M; Pillekamp, H; Schick, E; Sterry, W; Weber, L, 1995) |
| "Three patients are described with late-stage myeloproliferative diseases, two with accelerated phase chronic myelogenous leukemia (CML) and one with refractory polycythemia vera (P vera), who achieved hematologic control after the addition of interferon (IFN) to hydroxyurea therapy." | 3.69 | Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease. ( Landaw, SA; Litam, PP; Zamkoff, KW, 1994) |
| " We present an unusual Ph-positive CML case, which developed lymphoid blast crisis in complete cytogenetic remission following interferon-alpha and hydroxyurea therapy." | 3.69 | Lymphoid blast crisis during complete cytogenetic remission following interferon-alpha and hydroxyurea therapy. ( Bose, S; Chowdhry, VP; Kucheria, K; Saxena, R, 1997) |
| "We report a 44 year old man who developed external ophthalmoplegia and predominantly respiratory, truncal and bulbar weakness with brisk reflexes, histological evidence of an inflammatory myopathy and a high titre of acetylcholine receptor antibodies, one month after starting hydroxyurea and allopurinol for chronic myeloid leukaemia." | 3.68 | Complex neuromuscular disorder in a patient with chronic myeloid leukaemia. ( Bergin, PS; Gale, AN, 1993) |
| "The authors report about a successful labour and delivery after pregnancy with chronic myeloid leukemia treated with hydroxyurea." | 3.68 | [Successful delivery following continuous cytostatic therapy of a leukemic pregnant women]. ( Kovács, L; Szántó, F, 1993) |
| "The effect of hydroxyurea on blood viscosity was studied in 10 patients with Philadelphia chromosome positive chronic myelogenous leukemia (CML) and hyperleukocytosis (white blood cell counts over 200 x 10(9)/l)." | 3.68 | Effect of hydroxyurea on blood viscosity in chronic myelogenous leukemia with hyperleukocytosis. ( Bhat, SV; Rao, S; Sharma, K, 1991) |
| " Overexpression of P-170 without amplification of MDR-1 was found in four of 11 patients with chronic phase CML at diagnosis, seven of 16 patients treated with busulfan or hydroxyurea in chronic phase and four of 15 patients in blast crisis." | 3.68 | The role of the MDR-1/P-170 mechanism in the development of multidrug resistance in chronic myeloid leukemia. ( Dowding, C; Goldman, J; Paulsen, W; Weide, R, 1990) |
| "Dasatinib dose was frequently reduced, but with maintained excellent effect." | 2.80 | Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). ( Dreimane, A; Ehrencrona, H; Gedde-Dahl, T; Gjertsen, BT; Hjorth-Hansen, H; Höglund, M; Koskenvesa, P; Lotfi, K; Majeed, W; Markevärn, B; Mustjoki, S; Ohm, L; Olsson-Strömberg, U; Porkka, K; Remes, K; Richter, J; Simonsson, B; Söderlund, S; Stenke, L; Suominen, M, 2015) |
| "Except for chronic myeloid leukemia, which is defined by the presence of the Philadelphia (Ph) chromosome, and the classic Ph chromosome-negative MPNs (polycythemia vera, essential thrombocythemia, and primary myelofibrosis), clonal neutrophilic neoplasms historically have been challenging to diagnose and classify." | 2.72 | Diagnosis and management of neutrophilic myeloid neoplasms. ( Gotlib, J; Schwede, M; Shomali, W, 2021) |
| "Gender-related aspects in chronic myeloid leukemia (CML) have not been studied well." | 2.71 | Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. ( Berger, U; Hasford, J; Hehlmann, R; Heimpel, H; Hochhaus, A; Hossfeld, DK; Kolb, HJ; Lahaye, T; Löffler, H; Maywald, O; Pfirrmann, M; Pralle, H; Queisser, W; Reiter, A, 2005) |
| " Further objectives were to analyze pharmacodynamic effect on deoxynucleotides (dNTPs) and to seek relationships between the decrease in dNTP pools and inhibition of DNA synthesis in CML blasts." | 2.69 | Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia. ( Gandhi, V; Kantarjian, H; O'Brien, S; Plunkett, W; Robertson, LE; Talpaz, M, 1998) |
| "In 1994, the Italian and the German Chronic myeloid leukemia (CML) trials comparing interferon-alpha (IFN-alpha) with conventional chemotherapy were published." | 2.68 | Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha. ( Anseri, H; Baccarani, M; Hasford, J; Hehlmann, R; Tura, S; Zuffa, E, 1996) |
| "Five patients with Ph+ chronic myeloid leukemia and no detectable diploid cells in the marrow received 6 g hydroxyurea twice daily for 7 days followed by G-CSF to harvest Ph-cells 1-84 months after diagnosis." | 2.68 | High-dose hydroxyurea and G-CSF to collect Philadelphia-negative cells in chronic myeloid leukemia: preliminary results. ( Bell, J; Cabral, S; Mehta, J; Millar, B; Min, T; Powles, R; Shepherd, V; Singhal, S; Swansbury, GJ; Treleaven, J, 1996) |
| "Previously untreated patients with chronic myelogenous leukemia were randomly assigned to receive either hydroxyurea (50 mg per kilogram of body weight per day) and interferon alfa-2b (5 million units per square meter of body-surface area per day), or hydroxyurea and interferon in the same dosages plus monthly courses of cytarabine (20 mg per square meter per day, for 10 days)." | 2.68 | Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. ( Abgrall, JF; Bouabdallah, R; Chastang, C; Cheron, N; Guerci, A; Guilhot, F; Guyotat, D; Harousseau, JL; Maloisel, F; Michallet, M; Nicolini, F; Tanzer, J, 1997) |
| "Forty-eight patients with chronic myeloid leukemia (CML) in chronic phase (CP) were treated by autologous stem cells transplantation (ASCT) and alpha Interferon (IFN) with three approaches: 1) ASCT at diagnosis followed by IFN, 2) ASCT post IFN with cells collected after an interval from IFN discontinuance, followed by IFN, 3) ASCT in patients selected by cytoconversion obtained with IFN, performed soon after IFN discontinuance." | 2.67 | Management of chronic myeloid leukemia in chronic phase with autologous stem cell transplantation and alpha-2 interferon: cytogenetic and clinical results. ( Alimena, G; Cedrone, M; de Cuia, MR; Lo Coco, F; Mancini, M; Meloni, G; Montefusco, E; Nanni, M; Pinto, R; Rondinelli, MB, 1993) |
| "Thirty patients with chronic myeloid leukemia from 11 Israeli medical centers entered this study." | 2.67 | Treatment of chronic myeloid leukemia with interferon alpha (Roferon): results of the Israeli Study Group on CML. ( Berrebi, A; Lugassy, G; Rosensaft, J; Shtalrid, M, 1993) |
| "The clinical course of 196 patients with chronic myelocytic leukemia (CML) was studied." | 2.67 | [Evaluation of 196 patients with chronic myeloid leukemia based on a standard prognosis model]. ( Anger, B; Carbonell, F; Ganser, A; Heimpel, H; Robertson, J; Schmeiser, T; Sokal, JE, 1990) |
| "The use of hydroxyurea in chronic myeloid leukemia during pregnancy is unknown." | 2.67 | Use of hydroxyurea in chronic myeloid leukemia during pregnancy: a case report. ( Dukes, IA; Hull, JC; Patel, M, 1991) |
| "Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms, respectively characterized by erythrocytosis and thrombocytosis." | 2.52 | Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2015) |
| "Hydroxyurea was implicated in 51% of cases." | 2.44 | Dermatomyositis induced by drug therapy: a review of case reports. ( Gottlieb, AB; Seidler, AM, 2008) |
| "In two patients with Behcet's disease (BD) and rheumatoid arthritis (RA), CML developed after RD, in two patients with diffuse cutaneous systemic sclerosis and spondyloarthropathy, RD was diagnosed after CML." | 2.43 | Rheumatic diseases and chronic myelogenous leukemia, presentation of four cases and review of the literature. ( Aydogdu, I; Erkurt, MA; Kaya, E; Kuku, I; Senel, S, 2006) |
| "Treatment options for chronic myeloid leukemia (CML) are discussed." | 2.43 | Chronic myeloid leukemia: standard treatment options. ( Frame, D, 2006) |
| "One of the MPDs, chronic myeloid leukemia (CML), has the distinct cytogenetic abnormality of the Philadelphia chromosome." | 2.42 | Treatment paradigms in the management of myeloproliferative disorders. ( Fruchtman, SM, 2004) |
| "Its use in the treatment of essential thrombocythemia began later in 1950." | 2.41 | Treatment of the myeloproliferative disorders with 32P. ( Berlin, NI, 2000) |
| "Hydroxyurea is an antimetabolite agent used in the treatment of myeloproliferative disorders and sickle cell anaemia." | 2.41 | Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. ( Ardigò, M; Borroni, G; Mangiacavalli, S; Merante, S; Nolli, G; Passamonti, F; Vassallo, C, 2001) |
| "Sudden sensorineural hearing loss that presents as the initial sign of haematological disease is very rare." | 2.41 | Sudden hearing loss in chronic myelogenous leukaemia implicating the hyperviscosity syndrome. ( Chae, SW; Cho, JH; Hwang, SJ; Kang, HJ; Lee, JH, 2002) |
| "Several randomized clinical trials in chronic myeloid leukemia (CML) have reported better patient survival with interferon alfa (IFN alpha) than with standard chemotherapeutic agents, such as busulfan or hydroxyurea." | 2.40 | Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. ( , 1997) |
| "Tumor lysis syndrome is a very serious and sometimes life-threatening complication of cancer treatment." | 2.40 | Tumor lysis syndrome. ( Ezzone, SA, 1999) |
| "Chronic myelogenous leukemia is a clonal disorder of hematopoietic stem cells characterized by granulocytic leukocytosis, splenomegaly, and a specific chromosomal abnormality, the Philadelphia chromosome." | 2.39 | Update on therapy for chronic myelogenous leukemia. ( Weinberger, BB, 1994) |
| " The superiority of a therapeutic regimen in chronic phase CML seems to primarily depend on whether its pharmacology permits a sufficiently high dosage to achieve the necessary reduction of tumor burden." | 2.39 | Current aspects of drug therapy in Philadelphia-positive CML: correlation of tumor burden with survival. ( Hehlmann, R; Heimpel, H, 1996) |
| "The management of chronic myeloid leukemia (CML) patients who relapse after allogeneic bone marrow transplantation (BMT) is difficult." | 2.38 | Chronic myeloid leukemia: management of relapse after allogeneic bone marrow transplantation. ( Kumar, L, 1993) |
| "For uric acid, there was no statistically significant (p<0." | 1.62 | BCR-ABL Transcript Level as Compared to LDH and Uric Acid Among Chronic Myeloid Leukemic Patients. ( Edao, A; Hailemariam, TS; Kinde, S; Mehdi, M; Seifu, D, 2021) |
| "Several reports have described intracranial hemorrhage during the accelerated phase or blast crisis of CML, but few have described this complication during the chronic phase." | 1.62 | [Chronic-phase chronic myeloid leukemia with intracranial hemorrhage complicated with tumor lysis syndrome]. ( Aoki, T; Arakawa, Y; Ikeda, Y; Isobe, K; Koh, K; Kubota, Y; Kurihara, J; Mori, M; Oyama, C, 2021) |
| " After the nilotinib dosage was reduced to 400 mg, liver biopsy, also performed in 1996 + 20, revealed hypertrophy of renal small blood vessels and endothelial cells of the hepatic artery and loss of endothelial cells of the renal glomeruli, portal vein, and hepatic sinusoids." | 1.56 | Pathological findings suggesting vascular endothelial damage in multiple organs in chronic myelogenous leukemia patients on long-term tyrosine kinase inhibitor therapy. ( Hasegawa, G; Koda, R; Morita, S; Nagano, O; Seki, Y, 2020) |
| "Although very rare, intracranial hemorrhage should be considered as a possible complication in patients with atypical chronic myeloid leukemia, even in chronic phase, if they have hyperleukocytosis and thrombocytopenia." | 1.48 | Sudden Intracranial Hemorrhage in a Patient With Atypical Chronic Myeloid Leukemia in Chronic Phase. ( Adachi, S; Funaki, T; Hiramatsu, H; Kanda, K; Kato, I; Kouzuki, K; Muramatsu, H; Ogawa, S; Saida, S; Umeda, K; Yoshida, K, 2018) |
| "Treatment with hydroxyurea at a dosage of 18 mg/kg twice daily was not effective in controlling the high count of white blood cells." | 1.48 | Hydroxyurea-induced onychomadesis in a dog with chronic myeloid leukemia: A case report. ( Anjos, DSD; Calazans, SG; Costa, PB; Fonseca-Alves, CE; Magalhães, LF; Sierra, OR, 2018) |
| "We describe a rare case of secondary breast carcinoma after chronic myeloid leukemia (CML) in a 56-year-old woman." | 1.46 | Secondary breast carcinoma after completely remitted chronic myeloid leukemia following targeted tyrosine kinase inhibitor therapy. ( Bi, L; Duan, J; Fan, Z; Pan, L; Qiao, W; Wu, D; Yang, M, 2017) |
| "Polycythemia Vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characterized by erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus, and risk of leukemic or fibrotic transformation." | 1.46 | Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. ( Barbui, T; Tefferi, A, 2017) |
| "Leukostasis is one of the complications of CML, causing partial or total occlusion of microvasculature with a variety of clinical manifestations, mostly ophthalmic, neurologic or respiratory." | 1.42 | [CHRONIC MYELOID LEUKEMIA IN A YOUNG MALE PRESENTING WITH BILATERAL CALF PAIN DUE TO LEUKOSTASIS]. ( Lavie, M; Rottenstreich, A; Rottenstreich, M, 2015) |
| "Hydroxyurea is an antimetabolite that is widely used in the treatment of many benign and malignant conditions." | 1.42 | Hydroxyurea-induced oral ulceration. ( Almazrooa, S; Alsayes, F; Azher, F; Badawi, M, 2015) |
| "The BCR-ABL oncoprotein of chronic myelogenous leukemia (CML) displays exclusive cytoplasmic localization and constitutive tyrosine kinase activity leading to the activation of different pathways that favor cell proliferation and survival." | 1.39 | Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs. ( Conte, E; Di Raimondo, F; Manzella, L; Stagno, F; Stella, S; Tirrò, E; Vigneri, P, 2013) |
| "The chloromas are regarded as an early herald of a systemic relapse, rather than as a localised process." | 1.39 | Multiple skin chloromas: a rare presentation of chronic myelogenous leukaemia in chronic stable phase. ( Chaudhary, SC; Jain, N; Kumar, V; Mishra, S, 2013) |
| "In order to study the genomic instability of CML cells, we evaluated the ability of these cells to arrest mitotic division after exposure to hydroxyurea, a known genotoxic agent." | 1.37 | BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint. ( Branca, A; Chiarenza, A; Conticello, C; Di Raimondo, F; Giallongo, C; La Cava, P; Palumbo, GA; Parrinello, N; Spina, P; Stagno, F; Tibullo, D; Vigneri, P, 2011) |
| "He had no evidence of recurrence of gastric cancer, although he had a continuous poor appetite due to TS-1." | 1.36 | [Secondary chronic myelogenous leukemia following postoperative TS-1 therapy for advanced gastric cancer]. ( Imai, T; Machida, T; Shima, Y; Uemura, Y, 2010) |
| "On the other hand, CML and the treatment during pregnancy can have side effect on the mother and the fetus, so the patients should be monitored and treated in tertiary hospitals." | 1.36 | [Clinical analysis about the management and the perinatal outcomes of pregnancy with chronic myeloid leukemia]. ( Liang, MY; Wang, DP; Wang, SM; Zhang, XH, 2010) |
| "Hydroxyurea pretreatment was routinely introduced in all patients until complete hematologic remission." | 1.35 | [Imatinib therapy in chronic myeloid leukemia]. ( Egyed, M; Karádi, E; Kollár, B; Matolcsi, A; Rajnics, P, 2008) |
| "Using BCR-ABL-induced chronic myeloid leukemia (CML) as a cancer model, we recently identified arachidonate 5-lipoxygenase (5-LO) gene (Alox5) as a critical regulator for leukemia stem cells (LSCs) in CML." | 1.35 | The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia. ( Chen, Y; Li, D; Li, S, 2009) |
| "Hydroxyurea (HU) is an antineoplastic drug commonly used to treat chronic myeloproliferative disorders." | 1.33 | Hydroxyurea induced perimalleolar ulcers. ( Lakshmi, N; Saravu, K; Shastry, BA; Thomas, J; Velappan, P, 2006) |
| "She was under hydroxyurea treatment for chronic myeloid leukemia at the time." | 1.33 | Gottron's papules-like eruption developing under hydroxyurea therapy. ( Kovalev, J; Lurie, M; Munichor, M; Rosner, I; Slobodin, G, 2006) |
| "Chronic neutrophilic leukemia is an uncommon hematological entity." | 1.33 | [Chronic neutrophilic leukemia: a long-term analysis of seven cases and review of the literature]. ( Batár, P; László, R; Telek, B; Udvardy, M, 2006) |
| " Non-linear modulating influence was registered even at low dosage of cytostatics which actually could not affect leukemic cell viability." | 1.33 | [Modulating effect of antileukemia drugs on the cellular susceptibility in chronic myeloid leukemia to cytotoxic lymphocytes]. ( Antonenko, EV; Cherepovich, VS; Grinëv, VV; Lotkova, ES; Shakhlevich, EV, 2006) |
| "Hydroxyurea is an antineoplasic agent usually used in myeloproliferative syndromes, but also in other benign pathological circumstances." | 1.33 | [Leg ulcer due to hydroxyurea. A case report]. ( Debonne, JM; Diagne-Guèye, NM; Fall, F; Gning, SB; Mbaye, PS; Ndiaye, B, 2006) |
| "Here we report two cases of squamous cell carcinoma of the skin, which appeared in the photo-exposed areas in two elderly patients treated for advanced chronic myeloid leukemia with imatinib." | 1.32 | Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment. ( Audring, H; Baskaynak, G; Dörken, B; Kreuzer, KA; le Coutre, P; Riess, H; Schwarz, M; Zuber, J, 2003) |
| "She developed severe hypersensitivity pneumonitis soon after the drug was initiated and required intubation and mechanical ventilation." | 1.32 | Severe hypersensitivity pneumonitis associated with anagrelide. ( Brink, DJ; Mazer, MA; Raghavan, M, 2003) |
| " This is an adverse effect of hydroxyurea that is not infrequently seen but is difficult to recognise." | 1.32 | [Ulcers on the legs and feet: a seldom recognised side effect of hydroxyurea]. ( Janssen, JJ; Ossenkoppele, GJ, 2003) |
| " Adverse effects of IFN were similar in both age groups, but IFN dosage to achieve treatment goals was lower in older patients." | 1.32 | Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha. ( Berger, U; Engelich, G; Gnad, U; Hasford, J; Hehlmann, R; Heimpel, H; Heinze, B; Hochhaus, A; Hossfeld, DK; Kolb, HJ; Löffler, H; Maywald, O; Metzgeroth, G; Pfirrmann, M; Pralle, H; Queisser, W; Reiter, A, 2003) |
| "Hydroxyurea is a ribonucleotide diphosphate reductase inhibitor used in the treatment of patients with myeloproliferative disorders." | 1.32 | Metastatic squamous cell carcinoma of the skin in chronic myeloid leukaemia: complication of hydroxyurea therapy. ( Altaner, S; Demir, M; Pamuk, GE; Tek, M; Turgut, B; Vural, O, 2003) |
| "Hydroxyurea (HU) is an inhibitor of nucleotide synthesis extensively used to control the chronic phase of myeloid leukemia." | 1.32 | Hydroxyurea-induced apoptosis in an EBV-immortalized lymphoblastoid cell line. ( Bailly, C; Dassonneville, L; Fenaux, P; Huyghe, P, 2004) |
| " Thus, the efficacy of other antileukemic agents combined with ZOL should be evaluated experimentally." | 1.32 | Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. ( Kimura, S; Kuroda, J; Maekawa, T; Nogawa, M; Ottmann, OG; Sato, K; Segawa, H; Yuasa, T, 2004) |
| " Hydroxyurea at an increased dosage was effective in controlling the CML." | 1.32 | [Pure red cell aplasia occurring during the course of chronic myelogenous leukemia]. ( Kawauchi, K; Ogasawara, T; Ohkawa, S; Takei, K; Yasuyama, M, 2004) |
| "He had been diagnosed as having chronic myeloid leukemia in 1999, and since then, he had continued to take hydroxyurea (1500 mg/day) orally." | 1.32 | [Severe hyponatremia with consciousness disturbance caused by hydroxyurea in a patient with chronic myeloid leukemia]. ( Kurata, M; Maeda, A; Matsushita, A; Nagai, K; Takahashi, T; Tanaka, Y; Tani, M; Watanabe, N, 2004) |
| "A case of chronic myeloid leukemia displaying an uncommon t(21;22)(q22;q11) is reported." | 1.31 | Chronic myeloid leukemia with a rare variant Philadelphia translocation: t(9;22;21)(q34;q11;q22). ( Ameye, G; Dierlamm, J; Ferrant, A; Guillaume, B; Libouton, JM; Michaux, L; Straetmans, N; Vaerman, JL; Verellen-Dumoulin, C, 2000) |
| "Of the 124 patients without myelofibrosis at onset, 42% later transformed into the myelofibrotic subtype." | 1.31 | Changing patterns of histological subgroups during therapy of Ph1+ chronic myelogenous leukaemia. ( Kvasnicka, HM; Leder, LD; Schaefer, HE; Schmitt-Graeff, A; Thiele, J, 2000) |
| " The cytotoxic effects of STI571 were studied in combination with antileukemic agents against Ph(+) leukemia cell lines, KU812, K-562, TCC-S, and TCC-Y." | 1.31 | In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. ( Akutsu, M; Furukawa, Y; Honma, Y; Kano, Y; Mano, H; Sato, Y; Tsunoda, S, 2001) |
| "Thrombocytosis is a common clinical condition." | 1.31 | Thrombocytosis--report of a case. ( Pavithran, K; Somarajan, A; Thomas, M, 2000) |
| "The clinical importance of finding the Philadelphia chromosome in patients who seem to have ET is in assessing prognosis." | 1.31 | BCR-ABL positive essential thrombocythaemia: a variant of chronic myelogerous leukaemia or a distinct clinical entity: a special case report. ( Cheong, SK; Fadilah, SA, 2000) |
| "Hydroxyurea, which is a cell-cycle-specific agent, probably exacerbates the periodicity which may be present in some patients with myeloproliferative disease." | 1.31 | Hydroxyurea and periodicity in myeloproliferative disease. ( Bennett, M; Grunwald, AJ, 2001) |
| "Hydroxyurea has been implicated in the appearance of skin vasculitic ulceration, but this is the first case, according to our knowledge, where the development of BD was observed during hydroxyurea maintenance in the chronic phase of CML." | 1.31 | Behcet's disease in a patient with chronic myelogenous leukemia under hydroxyurea treatment: a case report and review of the literature. ( Loukopoulos, D; Nodaros, K; Rombos, J; Terpos, E; Vaiopoulos, G; Viniou, N, 2001) |
| "We report a patient with Philadelphia chromosome positive (Ph +ve) chronic myelogenous leukemia (CML), treated with hydroxyurea alone, who upon disease progression developed an additional Ph - ve clone containing chromosomal abnormalities typical of myelodysplastic syndrome (MDS)." | 1.31 | Coexistence of independent myelodysplastic and Philadelphia chromosome positive clones in a patient treated with hydroxyurea. ( Flamm, MJ; Murty, VV; Nichols, GL; Rao, PH, 2002) |
| "We report a 45-year-old male with chronic myelogenous leukemia (CML) who experienced skin ulcers of the left lateral malleolus and dorsum of both feet." | 1.30 | [Bilateral leg ulcers with pathologic evidence of small vessel vasculitis by skin biopsy during hydroxyurea therapy of chronic myelogenous leukemia]. ( Irimajiri, J; Ito, T; Kanazawa, A; Kawahara, Y; Kudo, H; Ohkubo, H; Tomiyama, J; Uchino, S; Yano, K, 1997) |
| "Hydroxyurea-treated cells showed a dose- and time-dependent increase in binding of 125I-labeled IFN-alpha (maximal 2." | 1.30 | Upregulation of interferon-alpha receptor expression in hydroxyurea-treated leukemia cell lines. ( Harada, H; Matsuzaki, M; Mohri, H; Ogawa, K; Okubo, T; Tamura, T, 1997) |
| "Transformed chronic myeloid leukemia (CML) has a dismal prognosis, and treatment with a variety of chemotherapeutic agents is extremely disappointing." | 1.30 | Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon-alpha combined with hydroxyurea. ( Heinemann, V; Jehn, U, 1998) |
| "Hydroxyurea is a chemotherapeutic agent used extensively for myeloproliferative disorders." | 1.30 | Multiple squamous cell carcinomas of the skin during long-term treatment with hydroxyurea. ( De Simone, C; Guerriero, C; Guidi, B; Rotoli, M; Tartaglione, R; Venier, A, 1998) |
| "A 59-year-old man with chronic myelogenous leukemia (CML) had a white-blood-cell (WBC) count of 55,400/microliter when admitted in July 1997, and was placed on oral hydroxyurea (HU) of 1,500 mg/day." | 1.30 | [Myositis caused by hydroxyurea in a patient with chronic myelogenous leukemia]. ( Ikeda, K; Ishibashi, T; Maruyama, Y; Mita, M; Shichishima, T, 1998) |
| "We describe a patient with chronic myeloid leukemia on interferon treatment, who developed BMN with symptoms and signs masquerading as interferon toxicity." | 1.30 | Bone marrow necrosis masquerading as interferon toxicity in chronic myeloid leukemia. ( Chim, CS; Lam, CK; Ma, SK, 1999) |
| "Treatment with hydroxyurea returned the WBC count to reference range within 2 months." | 1.30 | Chronic granulocytic leukemia in a dog. ( Fine, DM; Tvedten, HW, 1999) |
| "The effect of interferon-alpha (IFN) for chronic myeloid leukemia (CML) in the chronic phase (CP) was retrospectively evaluated in comparison with that of busulfan (BU) or hydroxyurea (HU) given alone." | 1.30 | A cytogenetic and fluorescence in situ hybridization evaluation of interferon-alpha in the treatment of chronic myeloid leukemia. ( Itoh, T; Kakishita, E; Takemoto, Y; Tamura, S, 1999) |
| "Philadelphia chromosome-positive chronic myelogenous leukemia was diagnosed in a now 37-year old woman 16 years ago." | 1.30 | Chronic myelogenous leukemia in chronic phase for 16 years: ongoing hematological remission and late minor cytogenetic response under minimal interferon maintenance therapy. ( Fiegl, M; Jäger, U; Mitterbauer, G; Pirc-Danoewinata, H; Weltermann, A, 1999) |
| "Reaferon is indicated in chronic myeloid leukemia without splenomegaly." | 1.29 | [Experience with the use of reaferon (alfa 2-interferon) for treating patients with chronic myeloleukemia]. ( Abdulkadyrov, KM; Balashova, VA; Blinov, MN; Glazanova, TV; Gritsaev, SV; Martynkevich, IS; Moiseev, SI; Rukavitsyn, OA; Shcherbakova, EG, 1995) |
| "Hydroxyurea was continued for two more years and the lesions worsened." | 1.29 | [Multiple keratosis induced by hydroxyurea]. ( Audhuy, B; Couilliet, D; Grange, F; Guillaume, JC; Krzisch, S; Schlecht, P, 1995) |
| "New developments in relation to chronic myelogenous leukemia (CML) are characterized by progress in knowledge of pathogenesis, diagnostic improvement such as nosology of Philadelphia-negative CML and diagnosis of minimal residual disease by molecular techniques, advances in drug therapy with hydroxyurea or interferon alpha, and progress in bone marrow transplantation through availability of unrelated donors." | 1.29 | [Chronic myeloid leukemia. State of the art, May 1993]. ( Hehlmann, R, 1994) |
| "A 67-year-old patient with chronic myeloid leukemia for 4 years rapidly developed multiple squamous-cell carcinomas on the scalp." | 1.29 | Multiple squamous-cell carcinomas of the scalp and chronic myeloid leukemia. ( Andrac, L; Angeli-Besson, C; Jacquet, P; Koeppel, MC; Sayag, J, 1995) |
| "Hydroxyurea was given for cytoreduction and the patient has been followed with no evidence of acute transformation for about one year." | 1.29 | [An elderly patient with Ph1-positive chronic myelomonocytic leukemia]. ( Iwamoto, T; Kikukawa, M; Shin, K; Takasaki, M; Uno, M; Yoneda, Y, 1996) |
| "A patient is reported who developed chronic myelogenous leukemia (CML) six years after renal transplantation, which was followed by immunosuppressive with azathioprine, and the published data on such an association are reviewed." | 1.29 | [Chronic myeloid leukemia after renal transplantation: report of a new case and review of the bibliography]. ( Cervantes, F; Esteve, J; Marín, P; Montserrat, E; Rozman, C; Sanz, L; Vilardell, J, 1996) |
| "Treatment of the myeloid blast phase of chronic granulocytic leukemia is still a major problem in clinical hematology." | 1.28 | Therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. ( Goudsmit, R; Ho, AD; Hunstein, W; Trümper, LH; van der Lelie, H, 1989) |
| "Monosomy 7 variant childhood chronic myelogenous leukemia (CML) is a rare, fatal leukemia that usually terminates in blast crisis." | 1.28 | Establishment of donor hematopoiesis after hydroxyurea-induced aplasia following allograft failure in a patient with monosomy 7 variant of childhood chronic myelogenous leukemia. ( Cassano, WF, 1989) |
| " The maintenance dosage was adjusted to the white blood cell count." | 1.28 | A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia. ( Anger, B; Bartram, C; Heimpel, H; Heinze, B; Leichtle, R; Porzsolt, F, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (2.57) | 18.7374 |
| 1990's | 195 (45.56) | 18.2507 |
| 2000's | 162 (37.85) | 29.6817 |
| 2010's | 50 (11.68) | 24.3611 |
| 2020's | 10 (2.34) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, Y | 1 |
| Reddi, D | 1 |
| McCracken, J | 1 |
| Iranzad, N | 1 |
| Rehder, C | 1 |
| Neff, J | 1 |
| Wang, E | 1 |
| Ahmad, N | 1 |
| Qayum, S | 1 |
| Jameel, A | 1 |
| Ali, A | 1 |
| Siraj, S | 1 |
| Ali, J | 1 |
| Yousafzai, YM | 1 |
| Kockerols, CCB | 1 |
| Geelen, I | 1 |
| Levin, MD | 1 |
| Janssen, JJWM | 1 |
| Dinmohamed, AG | 1 |
| Hoogendoorn, M | 1 |
| Cornelissen, JJ | 1 |
| Westerweel, PE | 1 |
| Al-Ghazaly, J | 1 |
| Al-Dubai, W | 1 |
| Noaman, Y | 1 |
| Abdullah, M | 1 |
| Al-Gharasi, L | 1 |
| Rosti, G | 2 |
| Seki, Y | 1 |
| Nagano, O | 1 |
| Koda, R | 1 |
| Morita, S | 1 |
| Hasegawa, G | 1 |
| Assi, R | 1 |
| Kantarjian, H | 6 |
| Keating, M | 1 |
| Pemmaraju, N | 1 |
| Verstovsek, S | 1 |
| Garcia-Manero, G | 1 |
| Ravandi, F | 1 |
| Borthakur, G | 1 |
| Dahl, J | 1 |
| Jabbour, E | 1 |
| Cortes, JE | 2 |
| Hailemariam, TS | 1 |
| Mehdi, M | 1 |
| Kinde, S | 1 |
| Seifu, D | 1 |
| Edao, A | 1 |
| Ugwu, NI | 1 |
| Okoye, AE | 1 |
| Ugwu, CN | 1 |
| Ibiam, FA | 1 |
| Nnachi, OA | 1 |
| Ugwu, GC | 1 |
| Okoh, NU | 1 |
| Oyama, C | 1 |
| Arakawa, Y | 1 |
| Ikeda, Y | 1 |
| Aoki, T | 1 |
| Kubota, Y | 1 |
| Isobe, K | 1 |
| Mori, M | 1 |
| Kurihara, J | 1 |
| Koh, K | 1 |
| Schwede, M | 1 |
| Gotlib, J | 1 |
| Shomali, W | 1 |
| Pan, L | 1 |
| Duan, J | 1 |
| Qiao, W | 1 |
| Bi, L | 1 |
| Wu, D | 1 |
| Fan, Z | 1 |
| Yang, M | 1 |
| Usui, N | 1 |
| Moyo, TK | 1 |
| Savona, MR | 1 |
| Kouzuki, K | 1 |
| Umeda, K | 1 |
| Saida, S | 1 |
| Kato, I | 1 |
| Hiramatsu, H | 1 |
| Funaki, T | 1 |
| Kanda, K | 1 |
| Muramatsu, H | 1 |
| Yoshida, K | 2 |
| Ogawa, S | 1 |
| Adachi, S | 1 |
| Anjos, DSD | 1 |
| Costa, PB | 1 |
| Magalhães, LF | 1 |
| Sierra, OR | 1 |
| Calazans, SG | 1 |
| Fonseca-Alves, CE | 1 |
| Dyagil, IS | 2 |
| Sholoyko, VV | 1 |
| Silayev, YO | 1 |
| Martina, ZV | 1 |
| Dmytrenko, IV | 1 |
| Tovstogan, AO | 1 |
| Fedorenko, VG | 1 |
| Shlyakhtychenko, TY | 1 |
| Minchenko, ZM | 1 |
| Stella, S | 1 |
| Tirrò, E | 1 |
| Conte, E | 1 |
| Stagno, F | 3 |
| Di Raimondo, F | 3 |
| Manzella, L | 1 |
| Vigneri, P | 2 |
| Kumar, V | 1 |
| Jain, N | 1 |
| Chaudhary, SC | 1 |
| Mishra, S | 1 |
| Hua, J | 1 |
| Iwaki, Y | 1 |
| Inoue, M | 1 |
| Hagihara, M | 1 |
| Park, SH | 1 |
| Chi, HS | 1 |
| Cho, YU | 1 |
| Jang, S | 1 |
| Park, CJ | 1 |
| Kim, DY | 1 |
| Lee, JH | 2 |
| Lee, KH | 1 |
| Grisouard, J | 1 |
| Ojeda-Uribe, M | 1 |
| Looser, R | 1 |
| Hao-Shen, H | 1 |
| Lundberg, P | 1 |
| Duek, A | 1 |
| Jeandidier, E | 1 |
| Karow, A | 1 |
| Skoda, RC | 1 |
| Han, Q | 1 |
| Sun, M | 1 |
| Wu, L | 1 |
| Chen, J | 1 |
| Wang, W | 2 |
| Liu, C | 1 |
| Chen, H | 2 |
| Du, G | 1 |
| Itzykson, R | 1 |
| Itzkson, R | 1 |
| Fenaux, P | 2 |
| Solary, E | 1 |
| Zhaleiko, IO | 1 |
| Perekhrestenko, TP | 1 |
| Bilko, DI | 1 |
| Bilko, NM | 1 |
| Hjorth-Hansen, H | 1 |
| Stenke, L | 4 |
| Söderlund, S | 1 |
| Dreimane, A | 1 |
| Ehrencrona, H | 1 |
| Gedde-Dahl, T | 1 |
| Gjertsen, BT | 1 |
| Höglund, M | 2 |
| Koskenvesa, P | 1 |
| Lotfi, K | 1 |
| Majeed, W | 1 |
| Markevärn, B | 1 |
| Ohm, L | 1 |
| Olsson-Strömberg, U | 4 |
| Remes, K | 1 |
| Suominen, M | 1 |
| Simonsson, B | 8 |
| Porkka, K | 1 |
| Mustjoki, S | 1 |
| Richter, J | 1 |
| Wang, S | 1 |
| Xu, H | 1 |
| Liu, Y | 1 |
| He, W | 1 |
| Yanamandra, U | 1 |
| Sahu, KK | 1 |
| Malhotra, P | 1 |
| Varma, S | 2 |
| Matsumura, I | 1 |
| Tefferi, A | 3 |
| Barbui, T | 2 |
| Edesa, WA | 1 |
| Abdel-malek, RR | 1 |
| King, KY | 1 |
| Matatall, KA | 1 |
| Shen, CC | 1 |
| Goodell, MA | 1 |
| Swierczek, SI | 1 |
| Prchal, JT | 1 |
| Rottenstreich, M | 1 |
| Lavie, M | 1 |
| Rottenstreich, A | 1 |
| Badawi, M | 1 |
| Almazrooa, S | 1 |
| Azher, F | 1 |
| Alsayes, F | 1 |
| Bandyopadhyay, D | 1 |
| Manna, S | 1 |
| Hajra, A | 1 |
| Bhattacharya, TD | 1 |
| Faraci, M | 1 |
| Matthes-Martin, S | 1 |
| Lanino, E | 1 |
| Morreale, G | 1 |
| Ferretti, M | 1 |
| Giardino, S | 1 |
| Micalizzi, C | 1 |
| Balduzzi, A | 1 |
| Payandeh, M | 1 |
| Sadeghi, M | 1 |
| Sadeghi, E | 1 |
| Karlíková, R | 1 |
| Široká, J | 1 |
| Friedecký, D | 1 |
| Faber, E | 2 |
| Hrdá, M | 1 |
| Mičová, K | 1 |
| Fikarová, I | 1 |
| Gardlo, A | 1 |
| Janečková, H | 1 |
| Vrobel, I | 1 |
| Adam, T | 1 |
| Huang, J | 1 |
| Wang, L | 1 |
| Chen, L | 1 |
| Qun, H | 1 |
| Yajing, X | 1 |
| Fangping, C | 1 |
| Xielan, Z | 1 |
| Hai, X | 1 |
| Guo, M | 2 |
| Gao, C | 1 |
| Zhou, J | 1 |
| Wu, Y | 1 |
| Cheng, Z | 1 |
| Shi, L | 1 |
| Feng, L | 1 |
| Li, YM | 1 |
| Lyu, DL | 1 |
| Seidler, AM | 1 |
| Gottlieb, AB | 1 |
| Egyed, M | 1 |
| Kollár, B | 1 |
| Rajnics, P | 1 |
| Karádi, E | 1 |
| Matolcsi, A | 1 |
| Dolai, TK | 1 |
| Bhargava, R | 1 |
| Mahapatra, M | 1 |
| Mishra, P | 1 |
| Seth, T | 1 |
| Pati, HP | 1 |
| Saxena, R | 2 |
| Dem, A | 1 |
| Diallo, M | 1 |
| Gaye Fall, MC | 1 |
| Dieng, MM | 1 |
| Gaye, M | 1 |
| Touré, P | 1 |
| Hochhaus, A | 14 |
| Li, JY | 1 |
| Xu, W | 1 |
| Wu, W | 1 |
| Zhu, Y | 1 |
| Qiu, HR | 1 |
| Zhang, R | 1 |
| Zhang, SJ | 1 |
| Qian, SX | 1 |
| Verma, D | 1 |
| Fava, C | 1 |
| Cortes, J | 3 |
| Dissemond, J | 1 |
| Körber, A | 1 |
| Reddy, KS | 1 |
| Schwartz, GE | 1 |
| Jamedhor, M | 1 |
| Jain, V | 1 |
| Gupta, K | 1 |
| Nagpal, N | 1 |
| Chen, Y | 1 |
| Li, D | 1 |
| Li, S | 1 |
| Mizutani, S | 1 |
| Kuroda, J | 2 |
| Shimizu, D | 1 |
| Horiike, S | 1 |
| Taniwaki, M | 1 |
| Hara, Y | 1 |
| Kamura, Y | 1 |
| Oikawa, A | 1 |
| Shichino, H | 1 |
| Mugishima, H | 1 |
| Goto, H | 2 |
| Uemura, Y | 1 |
| Imai, T | 1 |
| Machida, T | 1 |
| Shima, Y | 1 |
| Kälsch, H | 1 |
| Wieneke, H | 1 |
| Erbel, R | 1 |
| Wang, DP | 1 |
| Liang, MY | 1 |
| Zhang, XH | 1 |
| Wang, SM | 1 |
| Humlová, Z | 1 |
| Klamová, H | 3 |
| Janatková, I | 1 |
| Malíčková, K | 1 |
| Králíková, P | 1 |
| Sterzl, I | 1 |
| Roth, Z | 1 |
| Hamšíková, E | 1 |
| Vonka, V | 1 |
| Giallongo, C | 2 |
| La Cava, P | 2 |
| Tibullo, D | 2 |
| Parrinello, N | 2 |
| Barbagallo, I | 1 |
| Del Fabro, V | 1 |
| Conticello, C | 2 |
| Romano, A | 1 |
| Chiarenza, A | 2 |
| Palumbo, GA | 3 |
| Belli, C | 1 |
| Alú, MF | 1 |
| Alfonso, G | 1 |
| Bianchini, M | 1 |
| Larripa, I | 1 |
| Bhaskar, ME | 1 |
| Bennour, A | 1 |
| Ouahchi, I | 1 |
| Ben Youssef, Y | 1 |
| Zaier, M | 1 |
| Laatiri, MA | 1 |
| Harrabi, I | 1 |
| Meddeb, B | 2 |
| Elloumi, M | 1 |
| Khelif, A | 1 |
| Saad, A | 1 |
| Sennana, H | 1 |
| Branca, A | 1 |
| Spina, P | 1 |
| Li, YF | 1 |
| Deng, Z | 1 |
| Din, BH | 1 |
| Zhu, JB | 1 |
| Herberich, E | 1 |
| Hothorn, T | 1 |
| Budrukkar, A | 1 |
| Muttagi, S | 1 |
| Shahid, T | 1 |
| Chatturvedi, P | 1 |
| Banavali, S | 1 |
| Laskar, SG | 1 |
| Murthy, V | 1 |
| D'Cruz, A | 1 |
| Agarwal, JP | 1 |
| Montani, D | 1 |
| Bergot, E | 1 |
| Günther, S | 1 |
| Savale, L | 1 |
| Bergeron, A | 1 |
| Bourdin, A | 1 |
| Bouvaist, H | 1 |
| Canuet, M | 1 |
| Pison, C | 1 |
| Macro, M | 1 |
| Poubeau, P | 1 |
| Girerd, B | 1 |
| Natali, D | 1 |
| Guignabert, C | 1 |
| Perros, F | 1 |
| O'Callaghan, DS | 1 |
| Jaïs, X | 1 |
| Tubert-Bitter, P | 1 |
| Zalcman, G | 1 |
| Sitbon, O | 1 |
| Simonneau, G | 1 |
| Humbert, M | 1 |
| Razga, F | 1 |
| Jurcek, T | 1 |
| Jeziskova, I | 1 |
| Zackova, D | 1 |
| Dvorakova, D | 1 |
| Borsky, M | 1 |
| Mayer, J | 1 |
| Racil, Z | 1 |
| Nofal, A | 1 |
| El-Din, ES | 1 |
| Goel, N | 1 |
| Pangtey, B | 1 |
| Thakar, M | 1 |
| Raina, UK | 1 |
| Ghosh, B | 1 |
| Singer, MK | 1 |
| Assem, M | 1 |
| Abdel Ghaffar, AB | 1 |
| Morcos, NY | 1 |
| Bruchova, H | 1 |
| Borovanova, T | 1 |
| Brdicka, R | 1 |
| Leo, E | 1 |
| Krämer, A | 1 |
| Krasniqi, F | 1 |
| Hehlmann, R | 27 |
| Ho, AD | 2 |
| Müller, MC | 2 |
| Lahaye, T | 3 |
| Akel, S | 1 |
| Kolialexi, A | 1 |
| Mavrou, A | 1 |
| Metaxotou, C | 1 |
| Loukopoulos, D | 3 |
| Yataganas, X | 1 |
| Hentrich, M | 2 |
| Stoetzer, OJ | 2 |
| Salat, C | 2 |
| Ledderose, G | 1 |
| Kvasnicka, HM | 7 |
| Thiele, J | 8 |
| Schmitt-Graeff, A | 7 |
| Diehl, V | 5 |
| Niederle, N | 2 |
| Schaefer, HE | 6 |
| Berger, U | 5 |
| Reiter, A | 5 |
| Engelich, G | 2 |
| Kreil, S | 1 |
| Merx, K | 1 |
| Sastre, JL | 1 |
| Bravo, A | 1 |
| Tembrás, S | 1 |
| Gómez, R | 1 |
| Ulibarrena, C | 1 |
| Wisløff, F | 1 |
| Brinch, L | 1 |
| Hammerstrøm, J | 1 |
| Ohashi, N | 1 |
| Yonemura, K | 1 |
| Sugiura, T | 1 |
| Isozaki, T | 1 |
| Togawa, A | 1 |
| Fujigaki, Y | 1 |
| Yamamoto, T | 1 |
| Hishida, A | 2 |
| Liu, NS | 1 |
| O'Brien, S | 6 |
| Othieno-Abinya, NA | 1 |
| Nyabola, LO | 1 |
| Kiarie, GW | 1 |
| Ndege, R | 1 |
| Maina, JM | 1 |
| Garside, R | 3 |
| Round, A | 3 |
| Dalziel, K | 3 |
| Stein, K | 3 |
| Royle, P | 1 |
| Aragane, Y | 1 |
| Okamoto, T | 1 |
| Yajima, A | 1 |
| Isogai, R | 1 |
| Kawada, A | 1 |
| Tezuka, T | 1 |
| Baskaynak, G | 1 |
| Kreuzer, KA | 1 |
| Schwarz, M | 1 |
| Zuber, J | 1 |
| Audring, H | 1 |
| Riess, H | 1 |
| Dörken, B | 1 |
| le Coutre, P | 1 |
| Morel, F | 1 |
| Bris, MJ | 1 |
| Herry, A | 1 |
| Calvez, GL | 1 |
| Marion, V | 1 |
| Abgrall, JF | 2 |
| Berthou, C | 1 |
| Braekeleer, MD | 1 |
| Wahlin, A | 5 |
| Golovleva, I | 1 |
| Yamamoto, K | 1 |
| Matsushita, T | 1 |
| Tanimoto, M | 1 |
| Saito, H | 1 |
| Emi, N | 1 |
| Xiao, Z | 2 |
| Hao, Y | 2 |
| Liu, B | 2 |
| Qian, L | 2 |
| Rák, K | 1 |
| Au, WY | 1 |
| Ma, SK | 2 |
| Wan, TS | 1 |
| Wang, EP | 1 |
| Lau, TC | 1 |
| Kwong, YL | 1 |
| Rechner, I | 1 |
| Brito-Babapulle, F | 1 |
| Fielden, J | 1 |
| Dokekias, AE | 1 |
| Malanda, F | 1 |
| Mbalawa, ChG | 1 |
| Karincaoglu, Y | 1 |
| Kaya, E | 2 |
| Esrefoglu, M | 1 |
| Aydogdu, I | 2 |
| Pfirrmann, M | 4 |
| Metzgeroth, G | 2 |
| Maywald, O | 3 |
| Hasford, J | 11 |
| Hossfeld, DK | 9 |
| Kolb, HJ | 12 |
| Löffler, H | 8 |
| Pralle, H | 8 |
| Queisser, W | 7 |
| Griesshammer, M | 7 |
| Nerl, C | 1 |
| Kuse, R | 1 |
| Tobler, A | 3 |
| Eimermacher, H | 1 |
| Tichelli, A | 1 |
| Aul, C | 1 |
| Wilhelm, M | 1 |
| Fischer, JT | 1 |
| Perker, M | 1 |
| Scheid, C | 1 |
| Schenk, M | 2 |
| Weiss, J | 1 |
| Meier, CR | 1 |
| Kremers, S | 1 |
| Labedzki, L | 1 |
| Schmeiser, T | 2 |
| Lohrmann, HP | 1 |
| Heimpel, H | 20 |
| Oh, ST | 1 |
| Lee, DW | 1 |
| Lee, JY | 1 |
| Cho, BK | 1 |
| Raghavan, M | 1 |
| Mazer, MA | 1 |
| Brink, DJ | 1 |
| Janssen, JJ | 1 |
| Ossenkoppele, GJ | 1 |
| Normann, AP | 1 |
| Egeland, T | 1 |
| Madshus, IH | 1 |
| Heim, S | 1 |
| Tjønnfjord, GE | 1 |
| Gnad, U | 1 |
| Heinze, B | 9 |
| Pamuk, GE | 1 |
| Turgut, B | 1 |
| Vural, O | 1 |
| Demir, M | 1 |
| Tek, M | 1 |
| Altaner, S | 1 |
| Buesche, G | 1 |
| Hecker, H | 1 |
| Schmeil, A | 1 |
| Gomez, G | 1 |
| Herrmann, H | 1 |
| Kappler, M | 1 |
| Buhr, T | 1 |
| Kreipe, HH | 1 |
| Georgii, A | 4 |
| Ince, AT | 1 |
| Bölükbaş, C | 1 |
| Dalay, R | 1 |
| Sökmen, HM | 1 |
| Kurdaş, OO | 1 |
| Prabhash, K | 1 |
| Loknath, D | 1 |
| Babu, KG | 2 |
| Hasib, AG | 1 |
| Biswas, S | 1 |
| Bapsy, PP | 2 |
| Tripathi, AK | 1 |
| Ahmad, R | 1 |
| Sawlani, KK | 1 |
| Staib, P | 1 |
| Klose, J | 1 |
| Engels, K | 1 |
| Kriener, S | 1 |
| Welt, K | 1 |
| Ott, S | 1 |
| Weiss, JM | 1 |
| Scharffetter-Kochanek, K | 1 |
| Huyghe, P | 1 |
| Dassonneville, L | 1 |
| Bailly, C | 1 |
| Kimura, S | 1 |
| Segawa, H | 1 |
| Sato, K | 1 |
| Nogawa, M | 1 |
| Yuasa, T | 1 |
| Ottmann, OG | 1 |
| Maekawa, T | 1 |
| Yasuyama, M | 1 |
| Kawauchi, K | 1 |
| Takei, K | 1 |
| Ogasawara, T | 1 |
| Ohkawa, S | 1 |
| Noda, M | 1 |
| Shoda, T | 1 |
| Takimoto, Y | 1 |
| Okita, H | 1 |
| Gómez-Casares, MT | 1 |
| Vaqué, JP | 1 |
| Lemes, A | 1 |
| Molero, T | 1 |
| Delgado, MD | 1 |
| León, J | 1 |
| Kluin-Nelemans, HC | 2 |
| Buck, G | 1 |
| le Cessie, S | 2 |
| Richards, S | 2 |
| Beverloo, HB | 1 |
| Falkenburg, JH | 1 |
| Littlewood, T | 1 |
| Muus, P | 1 |
| Bareford, D | 1 |
| van der Lelie, H | 2 |
| Green, AR | 2 |
| Roozendaal, KJ | 1 |
| Milne, AE | 1 |
| Chapman, CS | 1 |
| Shepherd, P | 1 |
| Watanabe, N | 1 |
| Tani, M | 1 |
| Tanaka, Y | 1 |
| Kurata, M | 1 |
| Matsushita, A | 1 |
| Maeda, A | 1 |
| Nagai, K | 1 |
| Takahashi, T | 2 |
| Colla, S | 1 |
| Sammarelli, G | 1 |
| Voltolini, S | 1 |
| Crugnola, M | 1 |
| Sebastio, P | 1 |
| Giuliani, N | 1 |
| Kalambokis, G | 1 |
| Stefanou, D | 1 |
| Arkoumani, E | 1 |
| Kitsanou, M | 1 |
| Bourantas, K | 1 |
| V Tsianos, E | 1 |
| Fruchtman, SM | 1 |
| Price, A | 1 |
| Harrison, SJ | 1 |
| Johnson, PR | 1 |
| Holyoake, TL | 1 |
| Varma, D | 1 |
| Khurana, N | 1 |
| Singh, T | 1 |
| Nacinovic, AD | 1 |
| Miletic, B | 1 |
| Topljak-Polic, D | 1 |
| Balen, S | 1 |
| Stimac, D | 1 |
| Silver, RT | 2 |
| Ahlgren, T | 1 |
| Björkholm, M | 6 |
| Carlsson, K | 1 |
| Gahrton, G | 7 |
| Hast, R | 6 |
| Löfvenberg, E | 4 |
| Linder, O | 3 |
| Ljungman, P | 3 |
| Malm, C | 6 |
| Paul, C | 3 |
| Rödjer, S | 2 |
| Turesson, I | 7 |
| Udén, AM | 7 |
| Killander, A | 4 |
| Wadman, B | 1 |
| Westin, J | 1 |
| Vikrot, O | 2 |
| Zettervall, O | 2 |
| Oberg, G | 7 |
| Singhal, N | 1 |
| George, J | 1 |
| Curtin, NJ | 1 |
| Campbell, PJ | 1 |
| Mandava, N | 1 |
| Costakos, D | 1 |
| Bartlett, HM | 1 |
| Bjoreman, M | 5 |
| Carneskog, J | 2 |
| Karlsson, K | 1 |
| Grimfors, G | 2 |
| Karle, H | 1 |
| Nielsen, JL | 1 |
| Nilsson, J | 1 |
| Olsson, K | 1 |
| Stentoft, J | 1 |
| Vilén, L | 3 |
| Weis-Bjerrum, O | 2 |
| Bousquet, M | 1 |
| Quelen, C | 1 |
| De Mas, V | 1 |
| Duchayne, E | 1 |
| Roquefeuil, B | 1 |
| Delsol, G | 1 |
| Laurent, G | 1 |
| Dastugue, N | 1 |
| Brousset, P | 1 |
| Saviola, A | 1 |
| Fiorani, C | 1 |
| Ferrara, L | 1 |
| Mazzocchi, V | 1 |
| Zucchini, P | 1 |
| Temperani, P | 1 |
| Longo, G | 1 |
| Emilia, G | 1 |
| Torelli, G | 1 |
| Swords, R | 1 |
| Quinn, J | 1 |
| Fay, M | 1 |
| O'Donnell, R | 1 |
| Goldman, J | 2 |
| Murphy, PT | 1 |
| Rudolph, G | 1 |
| Haritoglou, C | 1 |
| Schmid, I | 1 |
| Hochhaus, F | 1 |
| Kampik, A | 1 |
| Breccia, M | 3 |
| Muscaritoli, M | 1 |
| Alimena, G | 4 |
| Perel, JM | 1 |
| McCarthy, C | 1 |
| Walker, O | 1 |
| Irving, I | 1 |
| Williams, B | 1 |
| Kennedy, GA | 1 |
| Senel, S | 1 |
| Erkurt, MA | 1 |
| Kuku, I | 1 |
| Florian, S | 1 |
| Esterbauer, H | 1 |
| Binder, T | 1 |
| Müllauer, L | 1 |
| Haas, OA | 1 |
| Sperr, WR | 1 |
| Sillaber, C | 1 |
| Valent, P | 1 |
| Saravu, K | 1 |
| Velappan, P | 1 |
| Lakshmi, N | 1 |
| Shastry, BA | 1 |
| Thomas, J | 1 |
| Underhill-Day, N | 1 |
| Pierce, A | 2 |
| Thompson, SE | 1 |
| Xenaki, D | 1 |
| Whetton, AD | 1 |
| Owen-Lynch, PJ | 1 |
| Bernardini, K | 1 |
| Lanthaler, AJ | 1 |
| Buratti, T | 1 |
| Mitterer, M | 1 |
| Zhang, GS | 1 |
| Liu, DS | 1 |
| Dai, CW | 1 |
| Li, RJ | 1 |
| Slobodin, G | 1 |
| Lurie, M | 1 |
| Munichor, M | 1 |
| Kovalev, J | 1 |
| Rosner, I | 1 |
| Cesar, JM | 1 |
| Cabello, P | 1 |
| Ferro, T | 1 |
| Navarro, JL | 1 |
| Lahiri, P | 1 |
| Chaudhuri, U | 1 |
| Chattopadhyay, A | 1 |
| Dasgupta, AK | 1 |
| Telek, B | 1 |
| Batár, P | 1 |
| Udvardy, M | 1 |
| László, R | 1 |
| Assouline, S | 1 |
| Benemacher, V | 1 |
| Gambacorti-Passerini, C | 1 |
| Gologan, R | 1 |
| Stoia, R | 1 |
| Radulescu, I | 1 |
| Georgescu, D | 1 |
| Ostroveanu, D | 1 |
| Cherepovich, VS | 1 |
| Shakhlevich, EV | 1 |
| Antonenko, EV | 1 |
| Lotkova, ES | 1 |
| Grinëv, VV | 1 |
| Braide, I | 1 |
| Carlson, K | 1 |
| Lerner, R | 1 |
| Nilsson, PG | 1 |
| Tidefeldt, U | 1 |
| Winqvist, I | 1 |
| Frame, D | 1 |
| Gentilini, F | 1 |
| Ostro, D | 1 |
| Cheung, K | 1 |
| Kamel-Reid, S | 1 |
| Lipton, JH | 3 |
| Gning, SB | 1 |
| Debonne, JM | 1 |
| Diagne-Guèye, NM | 1 |
| Ndiaye, B | 1 |
| Fall, F | 1 |
| Mbaye, PS | 1 |
| Weber, L | 1 |
| Schick, E | 1 |
| Merkel, M | 1 |
| Pillekamp, H | 1 |
| Sterry, W | 1 |
| D'Hondt, L | 1 |
| Delannoy, A | 2 |
| Docquier, C | 1 |
| Saitoh, H | 1 |
| Shibata, A | 5 |
| Carella, AM | 4 |
| Frassoni, F | 3 |
| Pollicardo, N | 1 |
| Pungolino, E | 1 |
| Podestà, M | 1 |
| Giordano, D | 1 |
| Ferrero, R | 1 |
| Soracco, M | 1 |
| Benvenuto, F | 1 |
| Figari, O | 1 |
| Genden, EM | 1 |
| Bahadori, RS | 1 |
| Gabor, EP | 1 |
| Abdulkadyrov, KM | 3 |
| Moiseev, SI | 1 |
| Shcherbakova, EG | 1 |
| Balashova, VA | 1 |
| Glazanova, TV | 1 |
| Rukavitsyn, OA | 3 |
| Martynkevich, IS | 1 |
| Gritsaev, SV | 1 |
| Blinov, MN | 1 |
| Grange, F | 1 |
| Couilliet, D | 1 |
| Audhuy, B | 1 |
| Krzisch, S | 1 |
| Schlecht, P | 1 |
| Guillaume, JC | 1 |
| Ansari, H | 4 |
| Adelberger, V | 1 |
| Hossfeld, K | 1 |
| Masuoka, H | 1 |
| Kobayashi, M | 1 |
| Kaito, K | 1 |
| Yoshida, M | 3 |
| Sekita, T | 1 |
| Saeki, A | 1 |
| Nishiwaki, K | 1 |
| Shimada, T | 1 |
| Ochiai, S | 1 |
| Ootsubo, H | 1 |
| Lei, KI | 1 |
| Wickham, NW | 1 |
| Johnson, PJ | 1 |
| Minden, M | 1 |
| Tura, S | 7 |
| Baccarani, M | 5 |
| Góra-Tybor, J | 1 |
| Robak, T | 1 |
| Jakó, J | 1 |
| Kantarjian, HM | 6 |
| Smith, TL | 2 |
| Beran, M | 2 |
| Pierce, S | 3 |
| Talpaz, M | 12 |
| Anand, S | 1 |
| Verma, H | 1 |
| Kumar, L | 2 |
| Singh, N | 1 |
| Litam, PP | 1 |
| Landaw, SA | 1 |
| Zamkoff, KW | 1 |
| Meloni, G | 1 |
| de Cuia, MR | 1 |
| Rondinelli, MB | 1 |
| Lo Coco, F | 1 |
| Montefusco, E | 3 |
| Mancini, M | 2 |
| Pinto, R | 1 |
| Nanni, M | 1 |
| Cedrone, M | 1 |
| Börkholm, M | 1 |
| Savage, DG | 2 |
| Goldman, JM | 7 |
| Weinberger, BB | 1 |
| Nese, M | 1 |
| de Bellis, R | 2 |
| Urtiarte, R | 1 |
| Di Landro, J | 1 |
| Pirard, C | 1 |
| Michaux, JL | 2 |
| Bourlond, A | 1 |
| Shepherd, PC | 3 |
| Allan, NC | 5 |
| Tosi, P | 1 |
| Visani, G | 2 |
| Ottaviani, E | 1 |
| Darnowski, JW | 1 |
| Kennedy, BJ | 2 |
| Zuffa, E | 5 |
| Russo, D | 1 |
| Fanin, R | 1 |
| Zaccaria, A | 2 |
| Fiacchini, M | 1 |
| Suttorp, M | 2 |
| Rister, M | 1 |
| Schmitz, N | 2 |
| Kister, P | 1 |
| Willer, A | 2 |
| Simon, M | 1 |
| Seifarth, W | 1 |
| Papakonstantinou, G | 1 |
| Saussele, S | 1 |
| Taylor, DL | 1 |
| Kerwick, AM | 1 |
| Elliott, SL | 1 |
| Rodwell, RL | 1 |
| Wright, SJ | 1 |
| Marlton, PV | 1 |
| Veleba, AR | 1 |
| Taylor, KM | 1 |
| Ask, A | 1 |
| Persson, L | 1 |
| Rehnholm, A | 1 |
| Frostesjö, L | 1 |
| Holm, I | 1 |
| Heby, O | 1 |
| Morra, E | 1 |
| Lazzarino, M | 1 |
| Liberati, AM | 1 |
| Bernasconi, P | 1 |
| Donti, E | 1 |
| Merante, S | 2 |
| Caricchi, P | 1 |
| Jackson, N | 1 |
| Shukri, A | 1 |
| Ali, K | 1 |
| Queisser, WP | 1 |
| Essers, U | 2 |
| Falge, C | 1 |
| Shtalrid, M | 1 |
| Lugassy, G | 1 |
| Rosensaft, J | 1 |
| Berrebi, A | 1 |
| Leber, B | 1 |
| Walker, IR | 1 |
| Rodriguez, A | 1 |
| McBride, JA | 1 |
| Carter, R | 1 |
| Brain, MC | 1 |
| Bergin, PS | 1 |
| Gale, AN | 1 |
| Uriarte, MR | 1 |
| Mori, MA | 1 |
| Cardoso, H | 1 |
| Kuss, BJ | 1 |
| Sage, RE | 1 |
| Shepherd, KM | 1 |
| Hardingham, J | 1 |
| Nicola, M | 1 |
| Szydlo, R | 1 |
| Horowitz, MM | 2 |
| Gale, RP | 2 |
| Ash, RC | 1 |
| Atkinson, K | 1 |
| Dicke, KA | 1 |
| Gluckman, E | 1 |
| Herzig, RH | 1 |
| Marmont, A | 1 |
| Hashimoto, S | 2 |
| Papi, M | 2 |
| Didona, B | 2 |
| DePità, O | 1 |
| Abruzzese, E | 2 |
| Stasi, R | 2 |
| Papa, G | 2 |
| Cavalieri, R | 2 |
| Szántó, F | 1 |
| Kovács, L | 1 |
| Cohen, PR | 1 |
| Fitzgerald, JM | 1 |
| McCann, SR | 1 |
| Ahmed, S | 1 |
| Anwar, M | 1 |
| Siddiqui, SA | 1 |
| Saleem, M | 1 |
| Ahmad, PA | 1 |
| Mushtaq, S | 1 |
| Schulze, E | 1 |
| Krahl, R | 1 |
| Thalmeier, K | 1 |
| Helbig, W | 1 |
| Oikawa, H | 1 |
| Utsugisawa, T | 1 |
| Murai, K | 1 |
| Narigasawa, Y | 1 |
| Miyairi, Y | 1 |
| Shimosegawa, K | 1 |
| Suzuki, T | 1 |
| Kuriya, S | 1 |
| Angeli-Besson, C | 1 |
| Koeppel, MC | 1 |
| Jacquet, P | 1 |
| Andrac, L | 1 |
| Sayag, J | 1 |
| Jehn, U | 2 |
| Pötscher, C | 1 |
| Heinemann, V | 2 |
| Mahé, B | 1 |
| Gaillard, F | 1 |
| Labadie, F | 1 |
| Papin, S | 1 |
| Letortorec, S | 1 |
| Moreau, P | 1 |
| Harousseau, JL | 3 |
| Milpied, N | 1 |
| Wei, CH | 1 |
| Yu, IT | 1 |
| Tzeng, CH | 1 |
| Fan, FS | 1 |
| Hsieh, RK | 1 |
| Chiou, TJ | 1 |
| Liu, JH | 1 |
| Chen, PM | 1 |
| Robertson, LE | 2 |
| Anseri, H | 1 |
| Johansson, B | 1 |
| Fioretos, T | 1 |
| Billström, R | 1 |
| Mitelman, F | 1 |
| Singh, BP | 1 |
| Gupta, NP | 1 |
| Choudhry, VP | 1 |
| Martinelli, G | 1 |
| Testoni, N | 1 |
| Zinzani, PL | 1 |
| Farabegoli, P | 1 |
| Arpinati, M | 1 |
| Amabile, M | 1 |
| De Vivo, A | 1 |
| Richards, SM | 1 |
| Guilhot, F | 9 |
| Horowitz, M | 1 |
| Kluin-Nelemans, J | 1 |
| Schaefer, U | 1 |
| Storb, R | 1 |
| Thaler, J | 2 |
| Karl, H | 1 |
| Lanng-Nielsen, J | 1 |
| Carulli, G | 1 |
| Papineschi, F | 1 |
| Azzarà, A | 1 |
| Ambrogi, F | 1 |
| Kattan, MW | 1 |
| Inoue, Y | 1 |
| Giles, FJ | 2 |
| Ozer, H | 1 |
| Huber, SL | 1 |
| Beck, JR | 1 |
| Gudi, R | 1 |
| Elizalde, A | 1 |
| Gogineni, SK | 1 |
| Macera, MJ | 1 |
| Badillo, A | 1 |
| Verma, RS | 1 |
| Gardner, L | 1 |
| Grosso, LE | 1 |
| Kimura, H | 1 |
| Mita, H | 1 |
| Horiuchi, S | 1 |
| Tanimura, A | 1 |
| Adachi, M | 1 |
| Hinoda, Y | 1 |
| Imai, K | 1 |
| Hasegawa, A | 1 |
| Ninomiya, H | 1 |
| Yanagisawa, K | 1 |
| Takada, K | 1 |
| Hasegawa, H | 1 |
| Hato, T | 1 |
| Yasukawa, M | 1 |
| Fujita, S | 1 |
| Khoroshko, ND | 1 |
| Turkina, AG | 1 |
| Zhuravlev, VS | 1 |
| Sokolova, MA | 1 |
| Mikhaĭlova, IN | 1 |
| Zakharova, AV | 1 |
| Domracheva, EV | 1 |
| Semenova, EA | 1 |
| Shin, K | 1 |
| Kikukawa, M | 1 |
| Yoneda, Y | 1 |
| Uno, M | 1 |
| Iwamoto, T | 1 |
| Takasaki, M | 2 |
| Mehta, J | 2 |
| Powles, R | 1 |
| Singhal, S | 2 |
| Swansbury, GJ | 1 |
| Millar, B | 1 |
| Shepherd, V | 1 |
| Bell, J | 1 |
| Min, T | 1 |
| Cabral, S | 1 |
| Treleaven, J | 1 |
| Sanz, L | 1 |
| Cervantes, F | 2 |
| Esteve, J | 1 |
| Vilardell, J | 1 |
| Marín, P | 2 |
| Rozman, C | 1 |
| Montserrat, E | 2 |
| Daoud, MS | 1 |
| Gibson, LE | 1 |
| Pittelkow, MR | 1 |
| Shammas, F | 1 |
| Meyer, P | 1 |
| Heikkila, R | 1 |
| Apeland, T | 1 |
| Gøransson, L | 1 |
| Berland, J | 1 |
| Kjellevold, K | 1 |
| Sureda, A | 1 |
| Hernández-Bronchud, M | 1 |
| Tomiyama, J | 1 |
| Yano, K | 1 |
| Uchino, S | 1 |
| Ito, T | 1 |
| Kudo, H | 1 |
| Irimajiri, J | 1 |
| Ohkubo, H | 1 |
| Kanazawa, A | 1 |
| Kawahara, Y | 1 |
| Derzko, CM | 1 |
| Curtis, J | 1 |
| Armenta, D | 1 |
| Espallargas, C | 1 |
| Paz, A | 1 |
| Rodríguez Martorel, J | 1 |
| Ladines, R | 1 |
| Alvarez, C | 1 |
| Román, J | 1 |
| Andrés, P | 1 |
| Tamura, T | 1 |
| Matsuzaki, M | 1 |
| Harada, H | 1 |
| Ogawa, K | 1 |
| Mohri, H | 2 |
| Okubo, T | 2 |
| Cakir, B | 1 |
| Sucak, G | 1 |
| Haznedar, R | 1 |
| Jacob, A | 1 |
| Griffiths, M | 1 |
| Larkins, S | 1 |
| Holmes, J | 1 |
| Lengfelder, E | 1 |
| Leib-Mösch, C | 1 |
| Jarosová, M | 1 |
| Divoký, V | 1 |
| Luhový, M | 1 |
| Komenda, S | 1 |
| Sulovská, I | 1 |
| Hubácek, J | 1 |
| Slezák, P | 1 |
| Papajik, T | 1 |
| Raida, L | 1 |
| Heczko, M | 1 |
| Indrák, K | 1 |
| Dutcher, JP | 1 |
| Coletti, D | 1 |
| Paietta, E | 1 |
| Wiernik, PH | 1 |
| Tanaka, M | 2 |
| Yamazaki, Y | 1 |
| Kondo, E | 1 |
| Hattori, M | 2 |
| Tsushita, K | 1 |
| Utsumi, M | 1 |
| Chastang, C | 1 |
| Michallet, M | 1 |
| Guerci, A | 1 |
| Maloisel, F | 2 |
| Bouabdallah, R | 1 |
| Guyotat, D | 1 |
| Cheron, N | 1 |
| Nicolini, F | 1 |
| Tanzer, J | 4 |
| Urabe, A | 1 |
| Sacchi, S | 1 |
| Koller, C | 1 |
| Kornblau, S | 1 |
| Estey, E | 1 |
| Keating, MJ | 1 |
| Bose, S | 1 |
| Chowdhry, VP | 1 |
| Kucheria, K | 1 |
| Cox, C | 1 |
| Nowicky, D | 1 |
| Young, R | 1 |
| Ojeda Gutiérrez, E | 1 |
| Arrieta Gallastegui, R | 1 |
| Bustos, JG | 1 |
| Pérez Piño, T | 1 |
| Rocha, R | 1 |
| Sánchez Godoy, P | 1 |
| Lozano, M | 1 |
| Bello López, JL | 1 |
| Hernández Navarro, F | 1 |
| Ben-Yehuda, D | 1 |
| Krichevsky, S | 1 |
| Rachmilewitz, EA | 1 |
| Avraham, A | 1 |
| Sahar, D | 1 |
| Rosenbaum, H | 1 |
| Paltiel, O | 1 |
| Zion, M | 1 |
| Ben-Neriah, Y | 1 |
| Jacobs, P | 1 |
| Wood, L | 1 |
| Zhang, MJ | 1 |
| Klein, JP | 1 |
| McGlave, PB | 2 |
| Passweg, JR | 1 |
| Rowlings, PA | 1 |
| Sobocinski, KA | 1 |
| Johnson, RJ | 2 |
| Smith, GM | 2 |
| Verfaillie, CM | 1 |
| Bhatia, R | 1 |
| Browne, P | 1 |
| Key, NS | 1 |
| Pratt, G | 1 |
| Rawstron, AC | 1 |
| Barnard, DL | 1 |
| Morgan, GJ | 1 |
| Bohn, J | 1 |
| Hansen, JP | 1 |
| Menné, T | 1 |
| Lennard, A | 2 |
| Storey, N | 1 |
| Dickinson, AM | 1 |
| Irving, JA | 1 |
| Rowe, D | 1 |
| Conn, JS | 1 |
| Proctor, SJ | 2 |
| Motomura, S | 1 |
| Sakai, R | 1 |
| Tomita, N | 1 |
| Fujimaki, K | 1 |
| Fujisawa, S | 1 |
| Takahashi, N | 1 |
| Maruta, A | 1 |
| Kodama, F | 1 |
| De Simone, C | 1 |
| Guerriero, C | 1 |
| Guidi, B | 1 |
| Rotoli, M | 1 |
| Venier, A | 1 |
| Tartaglione, R | 1 |
| Boqué, C | 1 |
| Grañena, A | 1 |
| Kikawada, M | 1 |
| Ichinose, Y | 1 |
| Kunisawa, A | 1 |
| Yanagisawa, N | 1 |
| Minemura, K | 1 |
| Kasuga, I | 1 |
| Yonemaru, M | 1 |
| Kawanishi, K | 1 |
| Toyama, K | 1 |
| Brizard, F | 1 |
| Chomel, JC | 1 |
| Veinstein, A | 1 |
| Rivet, J | 1 |
| Giraud, C | 2 |
| Kitzis, A | 2 |
| Brizard, A | 3 |
| Gandhi, V | 1 |
| Plunkett, W | 1 |
| Weinlich, G | 2 |
| Schuler, G | 1 |
| Greil, R | 2 |
| Kofler, H | 1 |
| Fritsch, P | 2 |
| Hilbe, W | 1 |
| Apfelbeck, U | 1 |
| Fridrik, M | 1 |
| Bernhart, M | 1 |
| Niessner, H | 1 |
| Abbrederis, K | 1 |
| Michlmayr, G | 1 |
| Pont, J | 1 |
| Linkesch, W | 2 |
| Hausmaninger, H | 1 |
| Arneitz, K | 1 |
| Baldinger, C | 1 |
| Duba, C | 1 |
| Eisterer, W | 1 |
| Konwalinka, G | 1 |
| Niederwieser, D | 1 |
| Gastl, G | 2 |
| Tsodikov, A | 1 |
| Hasenclever, D | 1 |
| Loeffler, M | 1 |
| Ikeda, K | 1 |
| Mita, M | 1 |
| Ishibashi, T | 1 |
| Shichishima, T | 1 |
| Maruyama, Y | 1 |
| Reichenberger, F | 1 |
| Muñoz, A | 1 |
| Bureo, E | 1 |
| Ortega, JJ | 1 |
| Richard, C | 1 |
| Olivé, T | 1 |
| Maldonado, MS | 1 |
| Madero, L | 1 |
| Díaz, MA | 1 |
| Suehiro, M | 1 |
| Kishimoto, S | 1 |
| Wakabayashi, T | 1 |
| Ikeuchi, A | 1 |
| Miyake, H | 1 |
| Takenaka, H | 1 |
| Okano, A | 1 |
| Hirai, H | 1 |
| Shimazaki, C | 1 |
| Yasuno, H | 1 |
| Kido, M | 1 |
| Tago, O | 1 |
| Fujiwara, H | 1 |
| Ito, M | 1 |
| Niwano, H | 1 |
| Kato, N | 1 |
| Kimura, K | 1 |
| Yasukawa, K | 1 |
| Lanigan, SW | 1 |
| Chim, CS | 1 |
| Lam, CK | 1 |
| Fine, DM | 1 |
| Tvedten, HW | 1 |
| Ezzone, SA | 1 |
| Woolf, SH | 1 |
| Appelbaum, FR | 1 |
| Anderson, J | 1 |
| Bennett, C | 1 |
| Lichtin, AE | 1 |
| Uettwiller, F | 1 |
| Laplace, A | 1 |
| Lioure, B | 1 |
| Herbrecht, R | 1 |
| Mark, M | 1 |
| Dufour, P | 1 |
| Pane, F | 1 |
| Mostarda, I | 1 |
| Selleri, C | 1 |
| Salzano, R | 1 |
| Raiola, AM | 1 |
| Luciano, L | 1 |
| Saglio, G | 1 |
| Rotoli, B | 1 |
| Salvatore, F | 1 |
| Udal'eva, VIu | 2 |
| Bessmel'tsev, SS | 2 |
| Itoh, T | 1 |
| Tamura, S | 1 |
| Takemoto, Y | 1 |
| Kakishita, E | 1 |
| Girinsky, T | 1 |
| Bonomi, M | 1 |
| Bayle, C | 1 |
| Yasuda, N | 1 |
| Ohmori, S | 1 |
| Usui, T | 1 |
| Guillaume, B | 1 |
| Ameye, G | 1 |
| Libouton, JM | 1 |
| Dierlamm, J | 1 |
| Vaerman, JL | 1 |
| Straetmans, N | 1 |
| Ferrant, A | 2 |
| Verellen-Dumoulin, C | 1 |
| Michaux, L | 1 |
| Rodriguez, J | 1 |
| Rios, MB | 1 |
| Smetana, K | 1 |
| Jirásková, I | 1 |
| Yeh, H | 1 |
| Lichtman, SM | 1 |
| Flores, F | 1 |
| Eaglstein, WA | 1 |
| Kirsner, RS | 1 |
| Chiba, K | 1 |
| Kurosawa, M | 1 |
| Kondo, T | 1 |
| Suzuki, S | 2 |
| Musashi, M | 1 |
| Asaka, M | 1 |
| Imamura, M | 1 |
| Hattori, Y | 1 |
| Oba, Y | 1 |
| Fiegl, M | 1 |
| Mitterbauer, G | 1 |
| Weltermann, A | 1 |
| Pirc-Danoewinata, H | 1 |
| Jäger, U | 1 |
| Baykal, C | 1 |
| Zengin, N | 1 |
| Coşkun, F | 1 |
| Güler, N | 1 |
| Ayhan, A | 1 |
| Chybicka, A | 2 |
| Bogusławska-Jaworska, J | 2 |
| Kałwak, K | 2 |
| Turkiewicz, D | 2 |
| Armata, J | 2 |
| Balcerska, A | 2 |
| Cwiklińska, M | 2 |
| Hicke-Roberts, A | 1 |
| Kaczmarek-Kanold, M | 2 |
| Kołecki, P | 1 |
| Kowalczyk, J | 2 |
| Krauze, A | 2 |
| Matysiak, M | 2 |
| Płoszyńska, A | 2 |
| Rokicka-Milewska, R | 2 |
| Sońta-Jakimczyk, D | 2 |
| Sikorska-Fic, B | 2 |
| Wiśniewska-Slusarz, H | 2 |
| Wysocki, M | 2 |
| Wachowiak, J | 2 |
| Hirri, HM | 1 |
| Green, PJ | 1 |
| Ghalaut, PS | 1 |
| Singh, V | 1 |
| Gupta, S | 1 |
| Tarumoto, T | 1 |
| Imagawa, S | 1 |
| Hotta, T | 1 |
| Ohmine, K | 1 |
| Nagai, T | 1 |
| Takatoku, M | 1 |
| Komatsu, N | 1 |
| Hatake, K | 1 |
| Ozawa, K | 2 |
| Polák, J | 1 |
| Koza, V | 1 |
| Cetkovský, P | 1 |
| Haskovec, C | 1 |
| Tsuda, H | 1 |
| Yamasaki, H | 1 |
| Ueda, R | 1 |
| Bundschuh, S | 1 |
| Biermann, T | 1 |
| Roessler, G | 1 |
| Wasmus, M | 1 |
| Zankovich, R | 3 |
| Berlin, NI | 1 |
| Cvetanovska, G | 1 |
| Blum, N | 1 |
| Celiloglu, M | 1 |
| Altunyurt, S | 1 |
| Undar, B | 1 |
| Leder, LD | 2 |
| Tóthová, E | 1 |
| Fricová, M | 1 |
| Stecová, N | 1 |
| Kafková, A | 1 |
| Mudronová, B | 1 |
| Svorcová, E | 1 |
| Guman, T | 1 |
| Raffac, S | 1 |
| Hlebasková, M | 1 |
| Murphy, J | 1 |
| Morley, SM | 1 |
| Schultheis, B | 2 |
| Pasternak, G | 2 |
| Heissig, B | 1 |
| Hörner, S | 1 |
| Tsurumi, H | 1 |
| Hara, T | 1 |
| Moriwaki, H | 1 |
| Takagi, K | 1 |
| Nakamura, T | 1 |
| Misaki, H | 1 |
| Ueda, T | 2 |
| Abhyankar, D | 1 |
| Shende, C | 1 |
| Saikia, T | 1 |
| Advani, SH | 2 |
| Oudat, R | 1 |
| Khan, Z | 1 |
| Glassman, AB | 1 |
| Topaly, J | 1 |
| Zeller, WJ | 1 |
| Fruehauf, S | 1 |
| Kano, Y | 1 |
| Akutsu, M | 1 |
| Tsunoda, S | 1 |
| Mano, H | 1 |
| Sato, Y | 1 |
| Honma, Y | 1 |
| Furukawa, Y | 1 |
| Brunstein, CG | 1 |
| Thomas, M | 1 |
| Pavithran, K | 1 |
| Somarajan, A | 1 |
| Puri, P | 1 |
| Woodcock, BE | 1 |
| O'Donnell, N | 1 |
| Ellies, P | 1 |
| Anderson, DF | 1 |
| Topuhami, A | 1 |
| Tseng, SC | 1 |
| Kapsali, E | 1 |
| Tsiara, S | 1 |
| Christou, L | 1 |
| Panteli, A | 1 |
| Bourantas, KL | 1 |
| Fadilah, SA | 2 |
| Cheong, SK | 1 |
| Vassallo, C | 1 |
| Passamonti, F | 1 |
| Ardigò, M | 1 |
| Nolli, G | 1 |
| Mangiacavalli, S | 1 |
| Borroni, G | 1 |
| Guarini, A | 1 |
| Petti, MC | 1 |
| Zepparoni, A | 1 |
| Vitale, A | 1 |
| Foa, R | 1 |
| Bennett, M | 1 |
| Grunwald, AJ | 1 |
| Vaiopoulos, G | 1 |
| Terpos, E | 2 |
| Viniou, N | 1 |
| Nodaros, K | 1 |
| Rombos, J | 1 |
| Gancberg, D | 1 |
| Dargent, JL | 1 |
| Verhest, A | 1 |
| Kentos, A | 1 |
| Feremans, W | 1 |
| Lohrisch, C | 1 |
| Kornreich, A | 1 |
| Buchdunger, E | 1 |
| Matter, A | 1 |
| Druker, BJ | 1 |
| Al-Rayes, HM | 1 |
| Al-Shaikh, AA | 1 |
| Halim, MA | 1 |
| Al-Qurashi, FS | 1 |
| Al-Jurf, MM | 1 |
| Yao, B | 1 |
| Pian, H | 1 |
| Mignozzi, M | 1 |
| Picca, S | 1 |
| Hambach, L | 1 |
| Eder, M | 1 |
| Dammann, E | 1 |
| Battmer, K | 1 |
| Stucki, A | 1 |
| Heil, G | 1 |
| Ganser, A | 3 |
| Hertenstein, B | 1 |
| Maury, S | 1 |
| Belhadj, K | 1 |
| Chami, I | 1 |
| Kuentz, M | 1 |
| Cordonnier, C | 1 |
| Bories, D | 1 |
| Olesen, LH | 1 |
| Pedersen, BB | 1 |
| Arnulf, B | 1 |
| Chebbi, F | 1 |
| Lefrere, F | 1 |
| Ait Arkoub, Z | 1 |
| Varet, B | 1 |
| Fillet, AM | 1 |
| Slavin, S | 1 |
| Ackerstein, A | 1 |
| Morecki, S | 1 |
| Gelfand, Y | 1 |
| Cividalli, G | 1 |
| de Bruijne, MH | 1 |
| van Houwelingen, HC | 1 |
| Goekce, D | 1 |
| Hernández-Boluda, JC | 1 |
| Carreras, E | 1 |
| Arellano-Rodrigo, E | 1 |
| Rovira, M | 1 |
| Solé, F | 1 |
| Lloveras, E | 1 |
| Espinet, B | 1 |
| Ocejo, A | 1 |
| Flamm, MJ | 1 |
| Murty, VV | 1 |
| Rao, PH | 1 |
| Nichols, GL | 1 |
| Voskaridou, E | 1 |
| Komninaka, V | 1 |
| Eftyhiadis, E | 1 |
| Mantzourani, M | 1 |
| Petukhov, VI | 1 |
| Strozha, IL | 1 |
| Bondare, DK | 1 |
| Antman, KH | 1 |
| Whetton, T | 1 |
| Chae, SW | 1 |
| Cho, JH | 1 |
| Kang, HJ | 1 |
| Hwang, SJ | 1 |
| Hur, M | 1 |
| Song, EY | 1 |
| Kang, SH | 1 |
| Shin, DH | 1 |
| Kim, JY | 1 |
| Park, SS | 1 |
| Cho, HI | 1 |
| Petzer, AL | 1 |
| Hochenburger, E | 1 |
| Haun, M | 1 |
| Duba, HCh | 1 |
| Grünewald, K | 1 |
| Hoflehner, E | 1 |
| Sill, H | 1 |
| Gunsilius, E | 1 |
| Bubała, H | 1 |
| Boruczkowski, D | 1 |
| Hicke, A | 1 |
| Kolecki, P | 1 |
| Staszak-Kowalska, R | 1 |
| Tomaszewska, R | 1 |
| Kawabata, H | 1 |
| Kamada, T | 1 |
| Takatsuka, Y | 1 |
| Takeuchi, S | 1 |
| Makino, T | 1 |
| Utsunomiya, A | 1 |
| Ahmad-Zailani, H | 1 |
| Soon-Keng, C | 1 |
| Norlaila, M | 1 |
| Sadamoto, Y | 1 |
| Matsumoto, M | 1 |
| Kubokawa, M | 1 |
| Ito, K | 1 |
| Kubo, H | 1 |
| Harada, N | 1 |
| Muta, K | 1 |
| Nawata, H | 1 |
| Takata, M | 1 |
| Yao, T | 1 |
| Oetken, C | 1 |
| von Willebrand, M | 1 |
| Autero, M | 1 |
| Ruutu, T | 1 |
| Andersson, LC | 1 |
| Mustelin, T | 1 |
| Steegmann, JL | 1 |
| Lavilla, E | 1 |
| Somolinos, N | 1 |
| Pérez-Sánchez, M | 1 |
| Lamana, M | 1 |
| Olmeda, F | 1 |
| Cámara, R | 1 |
| Arranz, R | 1 |
| Ferro, MT | 1 |
| Fernández-Rañada, JM | 1 |
| Tsukagoshi, S | 1 |
| Aitchison, R | 1 |
| Syndercombe-Court, D | 1 |
| Schey, S | 1 |
| Newland, AC | 1 |
| Delmer, A | 1 |
| Rio, B | 1 |
| Bauduer, F | 1 |
| Ajchenbaum, F | 1 |
| Marie, JP | 1 |
| Zittoun, R | 1 |
| Ready, N | 1 |
| Freeman, NJ | 1 |
| Carvalho, A | 1 |
| Cantonetti, M | 1 |
| Wickramanayake, PD | 1 |
| Tertian, G | 1 |
| Tchernia, G | 1 |
| Papiernik, E | 1 |
| Elefant, E | 1 |
| Mehta, BC | 1 |
| Kolitz, JE | 1 |
| Kempin, SJ | 1 |
| Schluger, A | 1 |
| Wong, GY | 1 |
| Berman, E | 1 |
| Jhanwar, S | 1 |
| Arlin, ZA | 1 |
| Gee, T | 1 |
| Clarkson, BD | 1 |
| Anger, B | 2 |
| Robertson, J | 1 |
| Sokal, JE | 1 |
| Carbonell, F | 1 |
| Broustet, A | 1 |
| Reiffers, J | 1 |
| Marit, G | 1 |
| Fiere, D | 1 |
| Jaubert, J | 1 |
| Reynaud, J | 1 |
| Pris, J | 1 |
| Bernard, P | 1 |
| Charrin, C | 1 |
| Wen, ZQ | 1 |
| Asano, S | 1 |
| Ogura, H | 1 |
| Tani, K | 1 |
| Inoue, T | 1 |
| Tojo, A | 1 |
| Lamagnère, JP | 1 |
| Tilly, H | 1 |
| Casassus, P | 1 |
| Ifrah, N | 1 |
| Rochant, H | 1 |
| Bauters, F | 1 |
| Dine, G | 1 |
| Sharma, K | 1 |
| Rao, S | 1 |
| Bhat, SV | 1 |
| Renfro, L | 1 |
| Kamino, H | 1 |
| Raphael, B | 1 |
| Moy, J | 1 |
| Sanchez, M | 1 |
| Vomvouras, S | 1 |
| Pakula, AS | 1 |
| Shaw, JM | 1 |
| Prange, E | 1 |
| Schaub, J | 1 |
| Patel, M | 1 |
| Dukes, IA | 1 |
| Hull, JC | 1 |
| Holm, J | 1 |
| Engman, K | 1 |
| Toumi, NH | 1 |
| Ben Abid, H | 1 |
| Ben Othman, T | 1 |
| Trabelsi, C | 1 |
| Boukef, K | 1 |
| Hafsia, A | 1 |
| Weide, R | 1 |
| Dowding, C | 1 |
| Paulsen, W | 1 |
| von Wussow, P | 1 |
| Malhotra, OP | 1 |
| Salam, SR | 1 |
| Ahmad, M | 1 |
| Mahon, FX | 1 |
| Dreyfus, B | 2 |
| Huret, JL | 2 |
| Klingebiel, T | 1 |
| Creutzig, U | 1 |
| Dopfer, R | 1 |
| Ehninger, G | 1 |
| Schmidt, H | 1 |
| Ritter, J | 1 |
| Niethammer, D | 1 |
| Jackson, GH | 1 |
| Wallis, J | 1 |
| Ledingham, J | 1 |
| Jim, RT | 1 |
| Snyder, AB | 1 |
| Barone, JG | 1 |
| DiGiacomo, JC | 1 |
| Barone, JE | 1 |
| Trümper, LH | 1 |
| Hunstein, W | 1 |
| Goudsmit, R | 1 |
| Ueki, K | 1 |
| Tsuchida, A | 1 |
| Murakami, H | 1 |
| Karasawa, M | 1 |
| Kobayashi, N | 1 |
| Omine, M | 1 |
| Naruse, T | 1 |
| Borgies, P | 1 |
| Van den Berghe, H | 1 |
| Cassano, WF | 1 |
| Kamath, NS | 1 |
| Satyamoorthy, K | 1 |
| Chitnis, MP | 1 |
| Porzsolt, F | 1 |
| Leichtle, R | 1 |
| Bartram, C | 1 |
| Desmarest, MC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial[NCT00816114] | 3,000 participants (Anticipated) | Observational | 2005-06-08 | Recruiting | |||
| An Open-Label, Randomized, Multicenter Phase II Trial Comparing the Depletion of Malignant Stem Cells With Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid[NCT00852566] | Phase 2 | 46 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Evaluation of the Therapeutic Effect of Hydroxyurea Pulse Therapy for Chronic Myeloid Leukemia Patients[NCT03515018] | Phase 3 | 60 participants (Anticipated) | Interventional | 2018-05-01 | Recruiting | ||
| PROSPECTIVE RANDOMISED STUDY TO COMPARE LOW-DOSE INTERFERON-ALPHA-n1 (WELLFERON) +/- HYDROXYUREA VS HIGH-DOSE INTERFERON-ALPHA-n1 (WELLFERON) +/- HYDROXYUREA IN PATIENTS WITH NEWLY DIAGONISED CHRONIC PHASE CHRONIC MYELOID LEUKAEMIA[NCT00002869] | Phase 3 | 800 participants (Anticipated) | Interventional | 1995-04-30 | Active, not recruiting | ||
| Efficacy and Safety of Pegylated Proline Interferon Alpha 2b (AOP2014) in Maintaining Deep Molecular Remissions in Patients With Chronic Myeloid Leukemia (CML) Who Discontinue ABL-Kinase Inhibitor Therapy - a Randomized Phase III, Multicenter Trial With P[NCT03117816] | Phase 3 | 214 participants (Actual) | Interventional | 2017-05-04 | Completed | ||
| Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia[NCT00390897] | Phase 4 | 360 participants | Interventional | 2003-07-31 | Completed | ||
| Phase I/II Trial of Donor Derived Cytokine Induced Killer (CIK) Cells Infusion for Relapsed Hematologic Malignancy After Haploidentical Stem Cell Transplantation[NCT03821519] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2019-01-13 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
62 reviews available for hydroxyurea and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Diagnosis and management of neutrophilic myeloid neoplasms.
Topics: Antineoplastic Agents; Disease Management; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyu | 2021 |
Therapy for Chronic Myelomonocytic Leukemia in a New Era.
Topics: Allografts; Cytarabine; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Stem | 2017 |
Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?
Topics: Allografts; Antineoplastic Agents; Blast Crisis; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, | 2013 |
[Treatment of chronic myeloid leukemia in chronic phase].
Topics: Allografts; Benzamides; Busulfan; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib | 2014 |
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Topics: Aspirin; Calreticulin; Diagnosis, Differential; Disease Management; Humans; Hydroxyurea; Janus Kinas | 2015 |
Dermatomyositis induced by drug therapy: a review of case reports.
Topics: Adult; Aged; Antibodies, Antinuclear; Autoimmune Diseases; Cyclophosphamide; Dermatomyositis; Etopos | 2008 |
Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemia.
Topics: Aged; Antineoplastic Agents; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; | 2010 |
[Chronic myeloid leukemia--treatment].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cytarabine; Enzyme Inhibi | 2002 |
[Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Aberrations; Fusion Proteins, | 2002 |
The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clinical Trials as To | 2002 |
Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Blast Crisis; China; Dose-Response Rela | 2002 |
[Current therapy of chronic myeloid leukemia].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Busulfan; Enzyme | 2003 |
Current CML therapy: progress and dilemma.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Fusion Proteins, bcr | 2003 |
Development of large genital ulcer due to hydroxyurea treatment in a patient with chronic myeloid leukemia and Behcet's disease.
Topics: Adult; Antineoplastic Agents; Behcet Syndrome; Female; Genital Diseases, Female; Humans; Hydroxyurea | 2003 |
Treatment paradigms in the management of myeloproliferative disorders.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Chlorambucil; Hydroxyurea; Interferon-alpha; Leukemia, | 2004 |
Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis.
Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Humans; Hydroxyurea; Imatinib Mesylate; In | 2004 |
Chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Busulfan; Humans; Hydroxyurea; Imatinib Mesylate; Interferons; Le | 2004 |
Rheumatic diseases and chronic myelogenous leukemia, presentation of four cases and review of the literature.
Topics: Adult; Aged; Behcet Syndrome; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL P | 2006 |
Chronic myeloid leukemia: standard treatment options.
Topics: Drug Therapy; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positiv | 2006 |
[Chronic myeloid leukemia--latest aspects and practical progress in recent years].
Topics: Adult; Bone Marrow Transplantation; Combined Modality Therapy; Humans; Hydroxyurea; Interferon-alpha | 1995 |
[The assessment of therapeutic success in chronic myeloid leukemia].
Topics: Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Humans; Hydroxyurea; Interferon-al | 1995 |
New perspectives with interferon alpha. The German CML study group experience.
Topics: Busulfan; Clinical Trials as Topic; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Ch | 1994 |
[Clinical pharmacology of hydroxyurea].
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myelopro | 1995 |
Approaches to the treatment of chronic myeloid leukemia.
Topics: Bone Marrow Transplantation; Busulfan; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic | 1994 |
Update on therapy for chronic myelogenous leukemia.
Topics: Bone Marrow Transplantation; Busulfan; Histocompatibility; Humans; Hydroxyurea; Interferon-alpha; Le | 1994 |
Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Cytarabine; Humans; Hydroxyurea; Inter | 1994 |
Therapeutic progress and comparative aspects in chronic myelogenous leukemia (CML): interferon alpha vs. hydroxyurea vs. busulfan and expression of MMTV-related endogenous retroviral sequences in CML. German CML Study Group.
Topics: Bone Marrow Transplantation; Busulfan; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Interferon-alp | 1994 |
Management of chronic myeloid leukaemia.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Blast Crisis; Bone Marrow Transplantation; Busulfan; Ch | 1994 |
Chronic myeloid leukemia: management of relapse after allogeneic bone marrow transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Clinical Trials as Topi | 1993 |
[Interferon therapy for chronic myelogenous leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Hydroxyurea; Immun | 1993 |
The management of elderly patients with myeloproliferative disorders.
Topics: Adult; Age Factors; Aged; Bone Marrow Transplantation; Busulfan; Chronic Disease; Humans; Hydroxyure | 1993 |
Chronic myelogenous leukemia: a review.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Ph | 1996 |
Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Decision Support Techniques; Humans; Hydroxyurea; Inte | 1996 |
Characterization of a complex translocation [t(4;9;22)(p16;q34;q11)] in chronic myelogenous leukemia by fluorescence in situ hybridization technique.
Topics: Allopurinol; Antineoplastic Agents; Bone Marrow; Busulfan; Chromosome Banding; Chromosome Mapping; C | 1996 |
Current aspects of drug therapy in Philadelphia-positive CML: correlation of tumor burden with survival.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Trans | 1996 |
The management of chronic myeloid leukaemia--a case history.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Bone Marrow Transplantation; Busulfan; | 1997 |
[Recent progress in therapy for chronic myelogenous leukemia].
Topics: Age Factors; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Cytarabine; Humans; Hydro | 1997 |
Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Humans; | 1997 |
Mobilisation and reinfusion of Philadelphia negative peripheral blood mononuclear cells in chronic myeloid leukaemia with hydroxyurea and G-CSF.
Topics: Adult; Antineoplastic Agents; Cell Separation; Female; Granulocyte Colony-Stimulating Factor; Hemato | 1997 |
[Chronic myelogenous leukemia with long-term hypoplasia induced by alpha-interferon and hydroxyurea].
Topics: Antineoplastic Agents; Bone Marrow; Female; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myeloge | 1998 |
[Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia].
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 1998 |
Hydroxyurea-related leg ulcers in a patient with chronic myelogenous leukemia: a case report and review of the literature.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, BCR-ABL Posit | 1999 |
Tumor lysis syndrome.
Topics: Adult; Antineoplastic Agents; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL P | 1999 |
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Moda | 1999 |
A case of bilateral heel ulcers associated with hydroxyurea therapy for chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Foot Ulcer; Heel; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-AB | 2000 |
[Changing concept of conventional therapy in chronic myelogenous leukemia].
Topics: Animals; Antineoplastic Agents; Chimera; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplan | 2000 |
Treatment of the myeloproliferative disorders with 32P.
Topics: Adult; Aged; Alkylating Agents; Chlorambucil; Clinical Trials as Topic; Combined Modality Therapy; D | 2000 |
Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta-analysis of three randomized trials. Chronic myeloid leukemia trialists' collaborative group.
Topics: Antineoplastic Agents; Busulfan; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positi | 2000 |
The biology and treatment of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Busulfan; Clinical Trials as Topic; Combined Modality Therapy; Cy | 2001 |
Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia.
Topics: Adult; Aged; Antimetabolites; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL P | 2001 |
Bcr-Abl inhibition as a modality of CML therapeutics.
Topics: Animals; Antineoplastic Agents; Benzamides; Binding Sites; Cell Division; Clinical Trials as Topic; | 2001 |
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation | 2001 |
[Management of complications in patients with chronic myelogenous leukemia].
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Graft vs Host Disease; Hematop | 2001 |
[Chronic myeloid leukemia: current pathogenetic aspects and new therapeutic approaches (a foreign literature review)].
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Clinical Trials as Topic; Humans; Hydr | 2001 |
Imatinib mesylate--a new oral targeted therapy.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance; | 2002 |
Sudden hearing loss in chronic myelogenous leukaemia implicating the hyperviscosity syndrome.
Topics: Blood Viscosity; Cochlea; Combined Modality Therapy; Follow-Up Studies; Hearing Loss, Sensorineural; | 2002 |
Lymphoid preponderance and the absence of basophilia and splenomegaly are frequent in m-bcr-positive chronic myelogenous leukemia.
Topics: Aged; Basophils; Female; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Leukemia, Myelogenous, Chron | 2002 |
Treatment choices in chronic myelogenous leukemia.
Topics: Adult; Aged; Bone Marrow Transplantation; Busulfan; Humans; Hydroxyurea; Interferon-alpha; Leukemia, | 1992 |
The evolution of hydroxyurea therapy in chronic myelogenous leukemia.
Topics: Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1992 |
Treatment of chronic myeloid leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Busulfan; Dose-Response Relationship, | 1987 |
[Chronic myelocytic leukemia].
Topics: Busulfan; Combined Modality Therapy; Humans; Hydroxyurea; Interferons; Leukemia, Myelogenous, Chroni | 1989 |
Therapeutic options in chronic myeloid leukaemia.
Topics: Blast Crisis; Bone Marrow Transplantation; Busulfan; Humans; Hydroxyurea; Leukemia, Myelogenous, Chr | 1989 |
62 trials available for hydroxyurea and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Administration Schedule; Female; Fol | 2015 |
[Effect of IFN-α on Cytokines in Serum of Patients with Chronic Myeloid Leukemia].
Topics: Antineoplastic Agents, Alkylating; Cytokines; Humans; Hydroxyurea; Immunologic Factors; Interferon-a | 2017 |
Effect of homoharringtonine on bone marrow CD34 + CD117 + cells in patients with chronic myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Cells; CD4 Antigens; Cell Count; F | 2012 |
Impact of bone marrow morphology on multivariate risk classification in chronic myelogenous leukemia.
Topics: Bone Marrow; Erythroid Precursor Cells; Female; Humans; Hydroxyurea; Interferon alpha-2; Interferon- | 2003 |
Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Child; Cyto | 2003 |
Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Bone Marrow; Bone Mar | 2003 |
Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cause of D | 2004 |
Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.
Topics: Adult; Drug Resistance; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positiv | 2005 |
Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Marrow Transplantation; Busulfan; Child; Dose-Respo | 2004 |
Gender aspects in chronic myeloid leukemia: long-term results from randomized studies.
Topics: Adult; Age Distribution; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplas | 2005 |
Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-up.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Denmark; F | 2005 |
Alpha-interferon in the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
Topics: Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prospective | 1995 |
Management of chronic myeloid leukemia in chronic phase with autologous stem cell transplantation and alpha-2 interferon: cytogenetic and clinical results.
Topics: Adult; Blood Component Transfusion; Blood Transfusion, Autologous; Bone Marrow; Bone Marrow Purging; | 1993 |
Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenic leukemia.
Topics: Adult; Bone Marrow Transplantation; Clone Cells; Combined Modality Therapy; Female; Hematopoietic St | 1993 |
[Treatment of chronic myeloid leukemia using alpha-interferon and hydroxyurea. Study of 30 cases].
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Female; Fever; Humans; Hydroxyurea; Immunologic | 1994 |
Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blast Crisis; Busulfan; Cross-Over Studies; Drug Resista | 1994 |
Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia.
Topics: Busulfan; Female; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, | 1994 |
Therapeutic progress and comparative aspects in chronic myelogenous leukemia (CML): interferon alpha vs. hydroxyurea vs. busulfan and expression of MMTV-related endogenous retroviral sequences in CML. German CML Study Group.
Topics: Bone Marrow Transplantation; Busulfan; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Interferon-alp | 1994 |
Evolving approaches with interferon alfa in chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hydroxyurea; Interferon a | 1993 |
Chronic myelogenous leukemia: progress in chemotherapy and evaluation of prognostic score 1. The German CML Study Group.
Topics: Busulfan; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; P | 1993 |
Treatment of Ph-positive chronic myeloid leukemia with alpha-interferon (ROFERON-A). The Italian Cooperative Study Group experience. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
Topics: Adult; Bone Marrow; Bone Marrow Transplantation; Cohort Studies; Female; Humans; Hydroxyurea; Immuno | 1993 |
Long-term follow-up results of alpha interferon therapy in chronic myelogenous leukemia at M. D. Anderson Cancer Center.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; | 1993 |
The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.
Topics: Adult; Busulfan; Female; Germany; Germany, West; Humans; Hydroxyurea; Immunologic Factors; Interfero | 1993 |
Treatment of chronic myeloid leukemia with interferon alpha (Roferon): results of the Israeli Study Group on CML.
Topics: Adolescent; Adult; Aged; Antibody Formation; Combined Modality Therapy; Female; Humans; Hydroxyurea; | 1993 |
Karyotypic conversion by interferon as preparative treatment for autologous BMT in Ph positive CML. Italian Cooperative Study Group (ICSG) on Chronic Myeloid Leukemia.
Topics: Adult; Bone Marrow Purging; Bone Marrow Transplantation; Combined Modality Therapy; Feasibility Stud | 1993 |
Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group.
Topics: Blast Crisis; Busulfan; Drug Resistance; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic | 1993 |
Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase.
Topics: Actuarial Analysis; Bone Marrow Transplantation; Busulfan; Follow-Up Studies; Humans; Hydroxyurea; L | 1993 |
Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon alpha and hydroxyurea: a novel approach.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Antineoplastic Agents; Antineoplastic Combined | 1995 |
Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older.
Topics: Age Factors; Aged; Antineoplastic Agents; Basophils; Bone Marrow; Chronic Disease; Fatigue; Follow-U | 1996 |
Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Female; Germany; Humans; Hydroxyurea; Immu | 1996 |
Interferon-alpha in the treatment of chronic myeloid leukemia. A summary and an update of the Italian studies.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Clinical Protocols; Combined Modali | 1996 |
Progress with interferon in CML--results of the MRC UK CML III study.
Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelo | 1996 |
Low-dose interferon-alpha 2b combined with hydroxyurea versus hydroxyurea alone for chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Combined Modality Therapy; Drug Tolerance; Female; Humans; Hydroxyurea; Inter | 1996 |
Intensive treatment in order to minimize the Ph-positive clone in CML. Danish-Swedish CML Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Comb | 1996 |
High-dose hydroxyurea and G-CSF to collect Philadelphia-negative cells in chronic myeloid leukemia: preliminary results.
Topics: Adult; Antineoplastic Agents; Cell Separation; Dose-Response Relationship, Drug; Female; Granulocyte | 1996 |
Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)-Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Busulfan; Female; Humans; Hydroxy | 1997 |
Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study Group.
Topics: Antineoplastic Agents; Busulfan; Cell Line; Genome, Human; Germany; Humans; Hydroxyurea; Leukemia, M | 1997 |
[Interferon-alpha in the treatment of patients with chronic myeloid leukemia].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Busulfan; Female; Humans; Hydroxyurea; Interf | 1997 |
A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Biopsy; Bone Marrow; Drug Administr | 1997 |
Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chil | 1997 |
Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow- | 1997 |
Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Cohort Studies; Female; Histocompatibility Testing; | 1998 |
Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha 2b for chronic myeloid leukemia. The Benelux CML Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up St | 1998 |
Autologous stem cell transplantation in chronic myeloid leukaemia using Philadelphia chromosome negative blood progenitors mobilised with hydroxyurea and G-CSF.
Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; Female; Granulocyte Colony-Stimulating Fact | 1998 |
Collection of Philadelphia-negative peripheral blood progenitor cells in unselected patients with chronic granulocytic leukaemia. Northern Regional Haematology Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Female; Fusion Proteins, bcr-ab | 1998 |
Does BCR-ABL genomic rearrangement persist in CML patients in complete remission after interferon alpha therapy?
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Artificial Gene Fusion | 1998 |
Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female | 1998 |
Regression with bounded outcome score: evaluation of power by bootstrap and simulation in a chronic myelogenous leukaemia clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Thera | 1998 |
BCR/ABL mRNA and the P210(BCR/ABL) protein are downmodulated by interferon-alpha in chronic myeloid leukemia patients.
Topics: Antineoplastic Agents; Bone Marrow Cells; Cells, Cultured; Dose-Response Relationship, Drug; Fusion | 1999 |
Monitoring treatment and survival in chronic myeloid leukemia. Italian Cooperative Study Group on Chronic Myeloid Leukemia and Italian Group for Bone Marrow Transplantation.
Topics: Adult; Age Distribution; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1999 |
[Low doses of alpha-interferon preparations in the treatment of patients with chronic myeloleukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2000 |
Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dose-Response Relationship, | 2001 |
High-dose hydroxyurea plus G-CSF mobilize BCR-ABL-negative progenitor cells (CFC, LTC-IC) into the blood of newly diagnosed CML patients at any time of hematopoietic regeneration.
Topics: Adult; Blood Component Removal; Drug Therapy, Combination; Female; Fusion Proteins, bcr-abl; Granulo | 2002 |
[Treatment with interferon alfa-2a in the chronic phase of Philadelphia-positive chronic myeloid leukemia].
Topics: Adolescent; Adult; Aged; Bone Marrow; Bone Marrow Diseases; Combined Modality Therapy; Female; Human | 1992 |
Recombinant alpha 2B interferon in combination with oral chemotherapy in late chronic phase chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Female; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Leukemia, | 1992 |
Chronic myelogenous leukemia: recent developments in prognostic evaluation and chemotherapy. The German CML Study Group.
Topics: Bone Marrow Transplantation; Busulfan; Female; Germany; Humans; Hydroxyurea; Interferon-alpha; Leuke | 1992 |
[Evaluation of 196 patients with chronic myeloid leukemia based on a standard prognosis model].
Topics: Biomarkers, Tumor; Blast Crisis; Busulfan; Clinical Trials as Topic; Female; Follow-Up Studies; Huma | 1990 |
Hydroxyurea versus interferon alfa-2b in chronic myelogenous leukaemia: preliminary results of an open French multicentre randomized study.
Topics: Adult; Aged; Female; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenou | 1991 |
A multicentre study of a randomized therapeutic protocol in previously untreated patients with Ph-positive chronic myelogenous leukaemia: interferon alfa-2b and hydroxyurea with or without cytosine arabinoside , preliminary results.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; | 1991 |
Use of hydroxyurea in chronic myeloid leukemia during pregnancy: a case report.
Topics: Adult; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pregnancy; Pre | 1991 |
[Multicenter prospective controlled study of therapy of chronic myeloid leukemia. Comparison of busulfan, hydroxyurea and interferon alpha (April 1990 status)].
Topics: Busulfan; Female; Follow-Up Studies; Humans; Hydroxyurea; Interferon Type I; Leukemia, Myelogenous, | 1991 |
Bone marrow transplantation in comparison with conventional therapy in children with adult type chronic myelogenous leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; C | 1990 |
305 other studies available for hydroxyurea and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Sequential Development of JAK2V617F Mutation and BCR-ABL1 Fusion in Individual Patients With Myeloproliferative Neoplasms.
Topics: Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-A | 2022 |
Clinical and laboratory relevance of JAK2 V617F and BCR-ABL co-existence in Philadelphia positive CML patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Child; Female; Fusion Proteins, b | 2021 |
The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era.
Topics: Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Protein Ki | 2022 |
Outcome of Imatinib Treatment in Yemeni Patients With Chronic Myeloid Leukemia and the Influence of Nonadherence to Treatment and Duration of Previous Hydroxyurea Therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Female; Humans; Hydroxyurea; Imatinib Me | 2020 |
Pathological findings suggesting vascular endothelial damage in multiple organs in chronic myelogenous leukemia patients on long-term tyrosine kinase inhibitor therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Substitution; Endothelium, Vascular; Huma | 2020 |
Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience.
Topics: Blast Crisis; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; P | 2021 |
BCR-ABL Transcript Level as Compared to LDH and Uric Acid Among Chronic Myeloid Leukemic Patients.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Developing Countries; Female; Fusion Proteins | 2021 |
Chronic Myeloid Leukaemia with Sudden Bilateral Deafness and Leg Ulcer Associated with Hydroxyurea Therapy.
Topics: Antineoplastic Agents; Hearing Loss, Bilateral; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenou | 2021 |
[Chronic-phase chronic myeloid leukemia with intracranial hemorrhage complicated with tumor lysis syndrome].
Topics: Adolescent; Blast Crisis; Humans; Hydroxyurea; Intracranial Hemorrhages; Leukemia, Myelogenous, Chro | 2021 |
Secondary breast carcinoma after completely remitted chronic myeloid leukemia following targeted tyrosine kinase inhibitor therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Car | 2017 |
JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).
Topics: Algorithms; Aniline Compounds; Antineoplastic Agents; Aspirin; Blood Transfusion; Dasatinib; Hematop | 2017 |
Sudden Intracranial Hemorrhage in a Patient With Atypical Chronic Myeloid Leukemia in Chronic Phase.
Topics: Adolescent; Humans; Hydroxyurea; Intracranial Hemorrhages; Leukemia, Myelogenous, Chronic, BCR-ABL P | 2018 |
Hydroxyurea-induced onychomadesis in a dog with chronic myeloid leukemia: A case report.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Diagnosis, Differential; Disease-Free Survival; Do | 2018 |
CASE OF DEVELOPMENT OF NON-HODGKIN'S MALIGNANT LYMPHOMA ON THE BACKGROUND OF CHRONIC MYELOID LEUKEMIA IN A PATIENT WHO SUFFERED OF THE CHORNOBYL ACCIDENT.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chernobyl Nuclear Accident; C | 2018 |
Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs.
Topics: Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; | 2013 |
Multiple skin chloromas: a rare presentation of chronic myelogenous leukaemia in chronic stable phase.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, | 2013 |
Tumor lysis syndrome soon after treatment with hydroxyurea followed by nilotinib in two patients with chronic-phase chronic myelogenous leukemia.
Topics: Adult; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nuc | 2013 |
Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment.
Topics: Adult; Alleles; Fusion Proteins, bcr-abl; Heterozygote; Humans; Hydroxyurea; Janus Kinase 2; Leukemi | 2013 |
Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia.
Topics: Clone Cells; Dasatinib; Female; Genes, abl; Humans; Hydroxyurea; Janus Kinase 2; Leukemia, Myelogeno | 2013 |
Primary distal femur T-cell lymphoma after allogeneic haematopoietic stem cell transplantation for chronic myeloid leukaemia: a rare case report and literature review.
Topics: Adult; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2014 |
Determination of the optimal chemotherapy drugs pretreatment time through cultivation of hemopoietic cells in CML-patients treated with tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Bone Marrow Cells; Busulfan; Drug Resistance, Neoplasm; Humans; Hydroxyurea; | 2014 |
Leukaemia cutis as the initial manifestation in a child with brachydactyly in chronic phase of chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Brachydactyly; Child; Diagnosis, Differential; Fingers; Humans; Hydroxyurea; | 2014 |
Photodermatosis secondary to hydroxyurea.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; | 2014 |
Impact of imatinib interruption and duration of prior hydroxyurea on the treatment outcome in patients with chronic myeloid leukemia: Single institution experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Adm | 2015 |
Comparative long-term effects of interferon α and hydroxyurea on human hematopoietic progenitor cells.
Topics: Aged; Animals; Cell Differentiation; Cell Proliferation; Female; Hematopoietic Stem Cells; Humans; H | 2015 |
[CHRONIC MYELOID LEUKEMIA IN A YOUNG MALE PRESENTING WITH BILATERAL CALF PAIN DUE TO LEUKOSTASIS].
Topics: Allopurinol; Bone Marrow Examination; Dasatinib; Diagnosis, Differential; Enzyme Inhibitors; Humans; | 2015 |
Hydroxyurea-induced oral ulceration.
Topics: Adult; Antineoplastic Agents; Fatal Outcome; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chr | 2015 |
Atypical CML with massive splenic infarct: an extremely rare presentation.
Topics: Abdominal Pain; Anemia; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Fatal Outcom | 2015 |
Two pregnancies shortly after transplantation with reduced intensity conditioning in chronic myeloid leukemia.
Topics: Adolescent; Antineoplastic Agents; Dasatinib; Disease-Free Survival; Drug Administration Schedule; F | 2016 |
Treatment and Survival in Patients with Chronic Myeloid Leukemia in a Chronic Phase in West Iran.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Hydroxyurea; Imatinib Mesylat | 2015 |
Metabolite Profiling of the Plasma and Leukocytes of Chronic Myeloid Leukemia Patients.
Topics: Amino Acids; Citric Acid Cycle; Drug Monitoring; Glycolysis; Humans; Hydroxyurea; Imatinib Mesylate; | 2016 |
Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia.
Topics: Adult; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Europe; Female; H | 2017 |
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Topics: Aspirin; Calreticulin; Diagnosis, Differential; Erythropoietin; Humans; Hydroxyurea; Interferon-alph | 2017 |
Quantification of hydroxyurea in human plasma by HPLC-MS/MS and its application to pharmacokinetics in patients with chronic myeloid leukaemia.
Topics: Acetonitriles; Chromatography, High Pressure Liquid; Humans; Hydrophobic and Hydrophilic Interaction | 2017 |
[Imatinib therapy in chronic myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Drug Administration Schedule; Female; Humans; Hydroxyurea; Imatin | 2008 |
Is imatinib safe during pregnancy?
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, | 2009 |
[Cutaneous complications of long-term hydroxyurea therapy].
Topics: Adult; Alopecia; Antineoplastic Agents; Atrophy; Female; Hand; Humans; Hydroxyurea; Leukemia, Myelog | 2008 |
Prognostic factors in chronic myeloid leukemia (CML).
Topics: Chromosomes, Human, Pair 9; Female; Gene Deletion; Genetic Predisposition to Disease; Genetic Testin | 2008 |
The negative prognostic impact of derivative 9 deletions in patients who received hydroxyurea treatment for chronic myelogenous leukemia in the chronic phase.
Topics: Adolescent; Adult; Aged; Chromosomes, Human, Pair 9; Female; Gene Deletion; Genetic Predisposition t | 2008 |
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Dasatinib; Drug Resistan | 2009 |
Hydroxyurea-induced ulcers on the leg.
Topics: Aged; Antineoplastic Agents; Diagnosis, Differential; Follow-Up Studies; Humans; Hydroxyurea; Leg Ul | 2009 |
A fertile XY/XX chimeric male with chronic myeloid leukemia in a minor 46,XX cell line and a history of polycythemia vera and trisomy 9 in the major 46,XY cell line.
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Chimera; Chromosomes, Human, Pair 9; Chromosom | 2009 |
Perimalleolar ulcers in hydroxyurea treated patients with concomitant chronic venous disease: diagnostic pitfalls.
Topics: Aged; Antineoplastic Agents; Chronic Disease; Humans; Hydroxyurea; Hyperpigmentation; Leukemia, Myel | 2005 |
The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia.
Topics: 5-Lipoxygenase-Activating Proteins; Animals; Benzamides; Carrier Proteins; Genes, abl; Humans; Hydro | 2009 |
[Case of pediatric chronic myeloid leukemia with bilateral visual loss onset].
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Child; Fusion Proteins, bcr-abl; Humans; Hydro | 2010 |
[Secondary chronic myelogenous leukemia following postoperative TS-1 therapy for advanced gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Benzamides; Drug Combinations; Fatal Outcome; Gastrectomy; Hu | 2010 |
Acute myocardial infarction in a patient with chronic myelocytic leukemia during chemotherapy with hydroxyurea.
Topics: Angioplasty, Balloon, Coronary; Anterior Wall Myocardial Infarction; Antineoplastic Agents; Aspirin; | 2010 |
[Clinical analysis about the management and the perinatal outcomes of pregnancy with chronic myeloid leukemia].
Topics: Adult; Antineoplastic Agents; Benzamides; Biopsy, Needle; Female; Follow-Up Studies; Humans; Hydroxy | 2010 |
Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment.
Topics: Adult; Antineoplastic Agents; Benzamides; C-Reactive Protein; Complement System Proteins; Dasatinib; | 2010 |
Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Cycle; Cytarabine; DNA D | 2011 |
Novel variant Ph translocation t(9;22;11)(q34;q11.2;p15)inv(9)(p13q34) in chronic myeloid leukemia involving a one-step mechanism.
Topics: Aged; Antineoplastic Agents; Benzamides; Chromosome Banding; Chromosome Inversion; Chromosomes, Huma | 2011 |
Nail changes in a patient with leukaemia.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; | 2011 |
Molecular cytogenetic study of derivative chromosome 9 deletion in chronic myeloid leukemia patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Deletion; Chromosomes, | 2012 |
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint.
Topics: Actins; Adult; Aged; Cell Cycle Proteins; Cell Proliferation; Cells, Cultured; Cytochalasin B; Cytok | 2011 |
Dunnett-type inference in the frailty Cox model with covariates.
Topics: Antineoplastic Agents; Busulfan; Computer Simulation; Data Interpretation, Statistical; Female; Huma | 2012 |
Second primary head and neck squamous cell cancers with aggressive behavior in patients with chronic myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cause of Death; Disease-Fr | 2012 |
Pulmonary arterial hypertension in patients treated by dasatinib.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Agents; Benzamides; | 2012 |
Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood.
Topics: Aged; Antigens, CD34; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Disease Progression; Fus | 2012 |
Hydroxyurea-induced dermatomyositis: true amyopathic dermatomyositis or dermatomyositis-like eruption?
Topics: Aged; Antineoplastic Agents; Dermatomyositis; Drug Eruptions; Female; Humans; Hydroxyurea; Leukemia, | 2012 |
Chronic myeloid leukemia presenting with bilateral central retinal vein occlusion and massive retinal infiltrates.
Topics: Adolescent; Allopurinol; Antineoplastic Agents; Benzamides; Bone Marrow; Drug Therapy, Combination; | 2012 |
Cytokine profiling as a prognostic markers in chronic myeloid leukemia patients.
Topics: Adult; Antineoplastic Agents; C-Reactive Protein; Female; Humans; Hydroxyurea; Interleukin-18; Inter | 2011 |
Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea.
Topics: Adult; Antimetabolites, Antineoplastic; Chronic Disease; Gene Expression Profiling; Gene Expression | 2002 |
Gangrene of the toes in a patient with chronic myelogenous leukemia after long-term hydroxyurea therapy.
Topics: Antineoplastic Agents; Gangrene; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positi | 2002 |
[Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells].
Topics: Amino Acid Substitution; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benz | 2002 |
Efficiency of interphase fluorescence in situ hybridization for BCR/ABL on peripheral blood smears for monitoring of CML patients: a comparison with bone marrow findings.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow; CD3 Complex; Fusion Proteins, bcr-abl; Humans | 2002 |
[Chronic myeloid leukemia--case report].
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Cytarabine; Humans; Hydroxyur | 2002 |
Leg ulcers associated with hydroxyurea therapy.
Topics: Aged; Female; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2003 |
[National guidelines for treatment of chronic myelogenous leukemia].
Topics: Adult; Aged; Antineoplastic Agents; Blast Crisis; Humans; Hydroxyurea; Interferon-alpha; Leukemia, M | 2003 |
Withdrawal of interferon-alpha results in prompt resolution of thrombocytopenia and hemolysis but not renal failure in hemolytic uremic syndrome caused by interferon-alpha.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Hemolysis; Hemolytic-Uremic Syndrome; Humans; | 2003 |
Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia.
Topics: Aged; Benzamides; Blast Crisis; Cytogenetic Analysis; Drug Resistance, Neoplasm; Female; Humans; Hyd | 2002 |
Chronic myeloid leukaemia at the Kenyatta National Hospital, Nairobi.
Topics: Adolescent; Adult; Age Distribution; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combine | 2002 |
Hydroxyurea-induced foot ulcer successfully treated with a topical basic fibroblast growth factor product.
Topics: Administration, Topical; Adult; Antineoplastic Agents; Drug Eruptions; Fibroblast Growth Factors; Fo | 2003 |
Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment.
Topics: Age Factors; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cocarcinogenesis; Co | 2003 |
Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
Topics: Aneuploidy; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast | 2003 |
Emergence of Philadelphia positive chronic myeloid leukaemia during treatment with hydroxyurea for Philadelphia negative essential thrombocythaemia.
Topics: Antineoplastic Agents; Bone Marrow Examination; Humans; Hydroxyurea; Interferon-alpha; Karyotyping; | 2003 |
Trisomy X in Philadelphia chromosome-negative cells during the course of Philadelphia chromosome-positive chronic myelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Chromosomes, Human, X; Clone Cells; Disease Progression; Female; Human | 2003 |
Concurrent mediastinal B cell lymphoma and chronic myeloid leukemia with an unusually favorable response to chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clone Cells; Combined Modal | 2003 |
Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capillary Leak Syndrome; Combined Modality Th | 2003 |
[Chronic myeloid leukemia. What's in the future therapy in Black Africa?].
Topics: Adult; Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 2003 |
Hydroxyurea-induced melanonychia concomitant with a dermatomyositis-like eruption.
Topics: Adolescent; Adult; Antineoplastic Agents; Dermatomyositis; Drug Eruptions; Humans; Hydroxyurea; Leuk | 2003 |
Severe hypersensitivity pneumonitis associated with anagrelide.
Topics: Adrenal Cortex Hormones; Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Drug Interactions; F | 2003 |
[Ulcers on the legs and feet: a seldom recognised side effect of hydroxyurea].
Topics: Aged; Antineoplastic Agents; Foot Ulcer; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chro | 2003 |
CD7 expression by CD34+ cells in CML patients, of prognostic significance?
Topics: Adult; Aged; Antigens, CD34; Antigens, CD7; Cell Adhesion; Female; Flow Cytometry; Humans; Hydroxyur | 2003 |
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 2003 |
Metastatic squamous cell carcinoma of the skin in chronic myeloid leukaemia: complication of hydroxyurea therapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Humans; Hydroxyurea; Leukemia, Myelogenous, C | 2003 |
Rapid resolution of portal vein thrombosis and noncirrhotic portal hypertension following cyto-reductive therapy in a patient with chronic myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Female; Humans; Hydroxyurea; Hypertension, Portal; Leukapheresis; Leuke | 2003 |
Chronic myeloid leukemia with osteolytic bone involvement.
Topics: Adult; Antineoplastic Agents; Blast Crisis; Disease Progression; Humans; Hydroxyurea; Leukemia, Myel | 2003 |
Reversible leg ulcer due to hydroxyurea in a case of chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, BCR-AB | 2003 |
Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Examination; Drug Evaluation; Hum | 2004 |
[Painful symmetrical ankle ulcerations. A 73-year old patient with chronic myeloid leukemia].
Topics: Aged; Ankle; Antineoplastic Agents; Debridement; Female; Humans; Hydroxyurea; Leg Ulcer; Leukemia, M | 2004 |
Hydroxyurea-induced apoptosis in an EBV-immortalized lymphoblastoid cell line.
Topics: Apoptosis; Bromodeoxyuridine; Cell Cycle; Cell Line, Transformed; Cell Membrane; Flow Cytometry; Her | 2004 |
Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines.
Topics: Antineoplastic Agents; Benzamides; Cell Death; Cell Division; Cell Line, Tumor; Cytarabine; Daunorub | 2004 |
[Pure red cell aplasia occurring during the course of chronic myelogenous leukemia].
Topics: Acute Disease; Antineoplastic Agents; Blood Transfusion; Cyclosporine; Hepatitis C; Humans; Hydroxyu | 2004 |
[Chronic myelogenous leukemia following therapy for pineal germinoma].
Topics: Adolescent; Antineoplastic Agents; Combined Modality Therapy; Germinoma; Humans; Hydroxyurea; Interf | 2004 |
C-myc expression in cell lines derived from chronic myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Busulfan; Cell Division; Cell Line, Tumor; Gene Expres | 2004 |
[Severe hyponatremia with consciousness disturbance caused by hydroxyurea in a patient with chronic myeloid leukemia].
Topics: Aged; Antineoplastic Agents; Consciousness Disorders; Humans; Hydroxyurea; Hyponatremia; Leukemia, M | 2004 |
e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Fusion Proteins, b | 2004 |
Fulminant bronchiolitis obliterans organizing pneumonia following 2 d of treatment with hydroxyurea, interferon-alpha and oral cytarabine ocfosfate for chronic myelogenous leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cryptogenic Organizing Pne | 2004 |
The Scotland Leukaemia Registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukaemia in 1999 and 2000.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Humans; Hydroxyurea; Im | 2004 |
Gamna Gandy bodies of spleen seen in CML: a causal association--a case report.
Topics: Antineoplastic Agents; Child; Humans; Hydroxyurea; Hypertension, Portal; Leukemia, Myelogenous, Chro | 2004 |
Massive subcutaneous bleeding as a first manifestation of chronic myeloid leukemia in chronic phase.
Topics: Adult; Antineoplastic Agents; Disseminated Intravascular Coagulation; Ecchymosis; Humans; Hydroxyure | 2004 |
The Philadelphia translocation and pre-existing myeloproliferative disorders.
Topics: Antineoplastic Agents; Benzamides; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Ch | 2005 |
Chronic myelogenous leukemia manifested as bilateral proliferative retinopathy.
Topics: Adult; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Fluorescein Angiogra | 2005 |
Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Humans; Hydroxyurea; Imatinib Mesylate; In | 2005 |
The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Autoantigens; C | 2005 |
Transition of polycythemia vera to chronic myeloid leukaemia.
Topics: Aged; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Polycythemia Ve | 2005 |
CML clonal evolution with resistance to single agent imatinib therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Transformation, Neoplastic; Clone C | 2005 |
Visual loss as a first sign of adult-type chronic myeloid leukemia in a child.
Topics: Blindness; Blood Cell Count; Child; Fluorescein Angiography; Hematopoietic Stem Cell Transplantation | 2005 |
Reduction of glycosylated hemoglobin with stable insulin levels in a diabetic patient with chronic myeloid leukemia responsive to imatinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Diabetes Mellitus | 2005 |
Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamid | 2005 |
Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benz | 2006 |
Hydroxyurea induced perimalleolar ulcers.
Topics: Aged; Ankle; Antineoplastic Agents; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, | 2006 |
Role of the C-terminal actin binding domain in BCR/ABL-mediated survival and drug resistance.
Topics: Actins; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Division; Cell Line, Tumor; Clo | 2006 |
Monolateral renal infarction and erythromelalgia in a case of chronic myelogenous leukemia.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides | 2006 |
Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone M | 2006 |
Gottron's papules-like eruption developing under hydroxyurea therapy.
Topics: Biopsy; Coronary Angiography; Dermatologic Surgical Procedures; Dermatomyositis; Fatal Outcome; Fema | 2006 |
Emergence of chronic myelogenous leukemia in a patient with primary thrombocythemia and absence of BCR/ABL rearrangement.
Topics: Aged; Antineoplastic Agents; Benzamides; Blood Platelets; Bone Marrow Cells; Cells, Cultured; Chromo | 2006 |
Platelet aggregation profile as a marker of hydroxyurea bioavailability through nitric oxide generation in chronic myelogenous leukemia.
Topics: Adult; Biological Availability; Blood Platelets; Cyclic GMP; Enzyme Inhibitors; Female; Humans; Hydr | 2006 |
[Chronic neutrophilic leukemia: a long-term analysis of seven cases and review of the literature].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Diagnosis, Differential; Humans; H | 2006 |
Simultaneous development of Philadelphia chromosome-positive and -negative leukemias in the same patient.
Topics: Aged; Benzamides; Cytogenetic Analysis; Diagnosis, Differential; Female; Follow-Up Studies; Humans; | 2006 |
Chronic myelomonocytic leukemia with overlap dysplastic/proliferative presentation.
Topics: Aged; Antineoplastic Agents; Fatal Outcome; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chro | 2007 |
[Modulating effect of antileukemia drugs on the cellular susceptibility in chronic myeloid leukemia to cytotoxic lymphocytes].
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Humans; Hydroxyurea; K562 Cell | 2006 |
Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined | 2006 |
Cocaine abuse may influence the response to imatinib in CML patients.
Topics: Adult; Antineoplastic Agents; Benzamides; Cocaine; Cocaine-Related Disorders; Cytochrome P-450 CYP3A | 2007 |
Chromosomal abnormalities in chronic myeloid leukemia: evidence of a hierarchy in imatinib treated cells.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Chromosome Aberrations; Cytogenetics; H | 2007 |
[Leg ulcer due to hydroxyurea. A case report].
Topics: Antineoplastic Agents; Female; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, BCR-A | 2006 |
[Dermatomyositis-like skin changes with long-term hydroxyurea (Litalir) therapy].
Topics: Aged; Biopsy; Dermatomyositis; Diagnosis, Differential; Dose-Response Relationship, Drug; Facial Der | 1995 |
Hypothyroidism and arthritis during interferon therapy.
Topics: Antibodies, Antinuclear; Arthritis; Autoimmune Diseases; Female; Humans; Hydroxyurea; Hypothyroidism | 1993 |
Levels of serum granulocyte colony-stimulating factor in patients with chronic myeloid leukemia.
Topics: Alkaline Phosphatase; Granulocyte Colony-Stimulating Factor; Humans; Hydroxyurea; Interferon-alpha; | 1993 |
Ph-negative blood progenitor cells (BPCs) can be recruited after chemotherapy and G-CSF during early hemopoietic recovery in patients at diagnosis of CML or pretreated only with hydroxyurea.
Topics: Cell Separation; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cells; Hum | 1994 |
Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenic leukemia (CML). Swedish CML-group.
Topics: Adult; Bone Marrow Transplantation; Female; Humans; Hydroxyurea; Interferons; Leukemia, Myelogenous, | 1994 |
Bilateral sensorineural hearing loss as a first symptom of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Audiometry; Female; Follow-Up Studies; Hearing Loss, Bilateral; Hearing Loss, | 1995 |
Prolonged survival and probable cure in chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Female; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, | 1995 |
[Experience with the use of reaferon (alfa 2-interferon) for treating patients with chronic myeloleukemia].
Topics: Adult; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Mar | 1995 |
[Multiple keratosis induced by hydroxyurea].
Topics: Female; Hand Dermatoses; Humans; Hydroxyurea; Keratosis; Leukemia, Myelogenous, Chronic, BCR-ABL Pos | 1995 |
[Bilateral ankle ulcers associated with hydroxyurea therapy for chronic myelogenous leukemia].
Topics: Foot Ulcer; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged | 1995 |
Severe hyponatremia due to syndrome of inappropriate secretion of antidiuretic hormone in a patient receiving interferon-alpha for chronic myeloid leukemia.
Topics: Adult; Humans; Hydroxyurea; Hyponatremia; Inappropriate ADH Syndrome; Injections, Subcutaneous; Inte | 1995 |
CML may not be part of HUS.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Disease Progression; Gr | 1995 |
[Leukemia, cytostatic therapy and pregnancy].
Topics: Antineoplastic Agents; Cytogenetics; Female; Humans; Hydroxyurea; Infant, Newborn; Leukemia, Myeloge | 1994 |
Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service.
Topics: Adolescent; Adult; Aged; Cell Count; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Interfe | 1995 |
Induction of apoptosis in chronic myelogenous leukemia lymphocytes by hydroxyurea and adriamycin.
Topics: Adult; Aged; Apoptosis; Cell Death; DNA Damage; Doxorubicin; Female; Humans; Hydroxyurea; In Vitro T | 1995 |
Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease.
Topics: Adult; Drug Therapy, Combination; Hematologic Tests; Humans; Hydroxyurea; Interferon-alpha; Leukemia | 1994 |
[Longitudinal melanonychia and hydroxyurea].
Topics: Female; Hand Dermatoses; Humans; Hydroxyurea; Hyperpigmentation; Leukemia, Myelogenous, Chronic, BCR | 1994 |
Use of interferon in the treatment of chronic myelogenous leukemia.
Topics: Clinical Trials as Topic; Follow-Up Studies; History, 20th Century; Humans; Hydroxyurea; Interferon | 1994 |
Severe cytopenias associated with the sequential use of busulphan and interferon-alpha in chronic myeloid leukaemia.
Topics: Adult; Aged; Bone Marrow Diseases; Busulfan; Combined Modality Therapy; Female; Humans; Hydroxyurea; | 1994 |
Hydroxyurea enhances 3'-azido-3'-deoxythymidine (AZT) cytotoxicity in human chronic myeloid leukemia models.
Topics: Bone Marrow; Bone Marrow Cells; Cells, Cultured; Colony-Forming Units Assay; Dose-Response Relations | 1994 |
Interferon alfa-2a for chronic myeloid leukemia.
Topics: Female; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, B | 1994 |
Interferon-alpha-2 (IFN) plus hydroxyurea for treatment of juvenile chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Humans; Hydroxyurea; Infant; Interfe | 1994 |
Discordant neutrophil alkaline phosphatase activity and cytogenetic response in chronic myeloid leukemia treated with alpha-interferon.
Topics: Adult; Alkaline Phosphatase; Chromosome Aberrations; Female; Gene Rearrangement; Genes, abl; Humans; | 1993 |
Development of resistance to hydroxyurea during treatment of human myelogenous leukemia K562 cells with alpha-difluoromethylornithine as a result of coamplification of genes for ornithine decarboxylase and ribonucleotide reductase R2 subunit.
Topics: Animals; Blotting, Northern; Blotting, Southern; Cricetinae; Cricetulus; DNA Probes; Drug Resistance | 1993 |
[Clinical study of chronic myelogenous leukemia].
Topics: Blast Crisis; Bone Marrow Transplantation; Busulfan; Granulocytes; Humans; Hydroxyurea; Interferon-a | 1993 |
Hydroxyurea treatment for chronic myeloid leukaemia during pregnancy.
Topics: Adult; Drug Administration Schedule; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BC | 1993 |
Reinduction of remission of chronic myeloid leukemia by donor leukocyte transfusion following relapse after bone marrow transplantation: recovery complicated by initial pancytopenia and late dermatomyositis.
Topics: Adult; Bone Marrow Transplantation; Chronic Disease; Combined Modality Therapy; Dermatomyositis; Fem | 1993 |
[Chronic myeloid leukemia. State of the art, May 1993].
Topics: Bone Marrow Transplantation; Combined Modality Therapy; Humans; Hydroxyurea; Interferon-alpha; Leuke | 1994 |
Complex neuromuscular disorder in a patient with chronic myeloid leukaemia.
Topics: Adult; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Humans; Hydroxyurea; Leukemia, M | 1993 |
Remission of Philadelphia positive chronic myelogenous leukemia associated with t(3;21) after bone marrow transplantation.
Topics: Adult; Blotting, Southern; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Chromosomes, Human, | 1993 |
High dose hydroxyurea in collection of Philadelphia chromosome-negative stem cells in chronic myeloid leukaemia.
Topics: Aged; Cell Separation; Female; Hematopoietic Stem Cells; Humans; Hydroxyurea; Leukemia, Myelogenous, | 1993 |
Multiple skin tumors on light-exposed areas during long-term treatment with hydroxyurea.
Topics: Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Hydroxyurea; Leukemia, Myelogenous, C | 1993 |
[Successful delivery following continuous cytostatic therapy of a leukemic pregnant women].
Topics: Adult; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Hydroxyurea; Infant, | 1993 |
The use of gemfibrozil in a patient with chronic myelogenous leukemia to successfully manage retinoid-induced hypertriglyceridemia.
Topics: Acne Vulgaris; Adult; Combined Modality Therapy; Cytarabine; Gemfibrozil; Humans; Hydroxyurea; Hyper | 1993 |
The combination of hydroxyurea and leucapheresis in the treatment of chronic myeloid leukaemia in pregnancy.
Topics: Adult; Combined Modality Therapy; Female; Humans; Hydroxyurea; Immunologic Factors; Incidence; Infan | 1993 |
Granulocytic sarcoma in patients with chronic myeloid leukaemia.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Daunorubicin; Female; Humans; | 1995 |
Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
Topics: Base Sequence; Bone Marrow Transplantation; Cytarabine; Fusion Proteins, bcr-abl; Hematopoiesis; Hem | 1995 |
Tetrasomy of Philadelphia chromosome in myeloblastic crisis of chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Fatal Outcome; Humans; Hydroxyurea; Im | 1995 |
Multiple squamous-cell carcinomas of the scalp and chronic myeloid leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Humans; Hydr | 1995 |
Occurrence of a T cell lymphoma in a patient with chronic myeloid leukemia treated with alpha interferon.
Topics: Anemia, Hemolytic, Autoimmune; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Pro | 1995 |
Trisomy 21 in acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Down Syndrome; Humans; Hydroxyure | 1996 |
[Chronic myeloid leukemia].
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Female; Humans; Hydroxyurea; | 1996 |
Abberant cytogenetic evolution pattern of Philadelphia-positive chronic myeloid leukemia treated with interferon-alpha.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; | 1996 |
Priapism as a presentation of hematological malignancy.
Topics: Adult; Antineoplastic Agents; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; | 1995 |
FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Bone Marrow Transplantati | 1996 |
Current controversies on the role of interferon-alpha for therapy of chronic myeloid leukemia.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Combined Modality Therapy; Humans; Hydroxyurea; | 1996 |
Alpha-2a-interferon administration and Fc gamma RIII expression on neutrophils from chronic myeloid leukemia.
Topics: Blast Crisis; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chro | 1996 |
ICE, mini-ICE or high-dose hydroxyurea to mobilize Philadelphia (Ph1)-negative PBPC in chronic myelogenous leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Hematopoietic Stem Cell Transp | 1996 |
Gancyclovir-induced megakaryocyte loss in chronic myelogenous leukemia post bone-marrow transplant.
Topics: Adult; Antineoplastic Agents, Alkylating; Antiviral Agents; Bone Marrow; Bone Marrow Transplantation | 1996 |
[An allogeneic bone marrow transplantation for chronic myelocytic leukemia with a large extramedullary tumor in the pelvic cavity].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Mo | 1996 |
[Successful treatment of combined interferon-alpha and hydroxycarbamide for chronic myelogenous leukemia following therapy for malignant lymphoma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 1996 |
[A modern therapeutic strategy in Ph-positive chronic myeloleukemia].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 1996 |
[An elderly patient with Ph1-positive chronic myelomonocytic leukemia].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chromosomes, Human, Pair 8; Humans; Hydroxyurea; Kar | 1996 |
[Chronic myeloid leukemia after renal transplantation: report of a new case and review of the bibliography].
Topics: Adult; Azathioprine; Cyclosporine; Female; Humans; Hydroxyurea; Immunosuppressive Agents; Incidence; | 1996 |
Hydroxyurea dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea.
Topics: Aged; Biopsy; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chro | 1997 |
Thrombotic microangiopathy in a patient with chronic myelogenous leukemia on hydroxyurea.
Topics: Antineoplastic Agents; Female; Hemolytic-Uremic Syndrome; Humans; Hydroxyurea; Leukemia, Myelogenous | 1997 |
[Bilateral leg ulcers with pathologic evidence of small vessel vasculitis by skin biopsy during hydroxyurea therapy of chronic myelogenous leukemia].
Topics: Antineoplastic Agents; Biopsy; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, BCR-A | 1997 |
Alpha-interferon and pregnancy in a patient with CML.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Clomiphene; Female; Fertility Agent | 1996 |
[Complete cytogenetic remission of chronic myeloid leukemia with low-dose interferon alfa-2b and monthly high-dose busulfan].
Topics: Adult; Antineoplastic Agents, Alkylating; Busulfan; Combined Modality Therapy; Drug Administration S | 1996 |
Upregulation of interferon-alpha receptor expression in hydroxyurea-treated leukemia cell lines.
Topics: Antineoplastic Agents; DNA-Binding Proteins; Dose-Response Relationship, Drug; Humans; Hydroxyurea; | 1997 |
Longitudinal pigmented nail bands during hydroxyurea therapy.
Topics: Antineoplastic Agents; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1997 |
t(3;21) following peripheral blood stem cell transplantation in chronic phase chronic myeloid leukaemia.
Topics: Adult; Antineoplastic Agents; Chromosome Banding; Chromosomes, Human, Pair 21; Chromosomes, Human, P | 1997 |
Achievement of a complete cytogenetic response with hydroxyurea in a patient with chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Bone Marrow; Chromosome Mapping; Chromosomes, Human, Pair 22; Chromosomes, Hu | 1997 |
Optimizing treatment for chronic myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hydroxyurea; Interferon alpha-2; | 1997 |
Lymphoid blast crisis during complete cytogenetic remission following interferon-alpha and hydroxyurea therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Female; Humans; Hydroxyurea; In Situ H | 1997 |
Hydroxyurea-related ankle ulcers in patients with myeloproliferative disorders: a case report and review of the literature.
Topics: Ankle; Antineoplastic Agents; Foot Ulcer; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-A | 1997 |
[Autologous transplantation of peripheral stem cells in patients with chronic myeloid leukemia after mobilization with high-dose hydroxyurea].
Topics: Adult; Antineoplastic Agents; Blood Component Removal; Female; Hematopoietic Stem Cell Mobilization; | 1997 |
Molecular follow-up of disease progression and interferon therapy in chronic myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Child; DNA Methylation; Female; Follow-Up Studies; Genes, abl; Humans; Hydr | 1997 |
Hazards of interferon therapy in chronic granulocytic leukaemia.
Topics: Adult; Antineoplastic Agents; Female; Humans; Hydroxyurea; Interferon Type I; Leukemia, Myelogenous, | 1997 |
Interferon-alpha restores beta1-integrin-dependent, collagen-mediated platelet aggregation in a patient with chronic myelogenous leukemia.
Topics: Collagen; Combined Modality Therapy; Female; Humans; Hydroxyurea; Immunophenotyping; Integrin beta1; | 1998 |
Ulcerative lichen planus-like dermatitis due to long-term hydroxyurea therapy.
Topics: Aged; Antineoplastic Agents; Biopsy, Needle; Diagnosis, Differential; Foot Dermatoses; Humans; Hydro | 1998 |
Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon-alpha combined with hydroxyurea.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Female; Humans; Hydroxyur | 1998 |
Multiple squamous cell carcinomas of the skin during long-term treatment with hydroxyurea.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Face; Humans; Hydroxyurea; Leukemia, Myelogen | 1998 |
Sarcoidosis induced by interferon therapy for chronic myelogenous leukaemia.
Topics: Adult; Antineoplastic Agents; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, | 1998 |
Is hydroxyurea leukemogenic in essential thrombocythemia?
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Bone Marrow; Busulfan; Chromosome Aberrations; Chr | 1998 |
Leg ulcers associated with long-term hydroxyurea therapy.
Topics: Aged; Antineoplastic Agents; Female; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, | 1998 |
Questions raised by the Benelux CML Study Group: results from the randomized study with hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha2b for chronic myeloid leukemia.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Rel | 1998 |
Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chil | 1998 |
[Myositis caused by hydroxyurea in a patient with chronic myelogenous leukemia].
Topics: Antineoplastic Agents; Drug Therapy, Combination; Humans; Hydroxyurea; Interferon-alpha; Leukemia, M | 1998 |
[Symmetrical foot ulcer in chronic myeloid leukemia treated with hydroxyurea (Litalir)].
Topics: Aged; Antineoplastic Agents; Diagnosis, Differential; Female; Foot Ulcer; Humans; Hydroxyurea; Leuke | 1998 |
Treatment of Ph1-positive chronic myelogenous leukemia in children: comparison between allogeneic bone marrow transplantation and conventional chemotherapy. Spanish Working Party for BMT in Children (GETMON).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; C | 1998 |
Mini-ICE protocol is better than high-dose hydroxyurea to mobilize Ph-negative cells in earlier phases of chronic myelogenous leukemia.
Topics: Adult; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Hydrox | 1998 |
Hydroxyurea dermopathy with a dermatomyositis-like eruption and a large leg ulcer.
Topics: Antineoplastic Agents; Drug Eruptions; Female; Hand Dermatoses; Humans; Hydroxyurea; Leg Ulcer; Leuk | 1998 |
Leg ulcer associated with hydroxyurea treatment in a patient with chronic myelogenous leukaemia: successful treatment with prostagladin E1 and pentoxifylline.
Topics: Alprostadil; Antineoplastic Agents; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, | 1998 |
Leg ulceration with associated thrombocytosis: healing of ulceration associated with treatment of the raised platelet count.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, BCR-ABL Posit | 1999 |
Bone marrow necrosis masquerading as interferon toxicity in chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Bone Marrow; Diagnosis, Differential; Humans; Hydroxyurea; Interferon | 1999 |
[Interferon-alpha in the treatment of chronic myeloid leukemia].
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Age | 1999 |
Chronic granulocytic leukemia in a dog.
Topics: Alopecia; Animals; Antineoplastic Agents; Biopsy; Bone Marrow; Dog Diseases; Dogs; Female; Hydroxyur | 1999 |
Leg ulcers in patients treated with hydroxyurea for myeloproliferative disorders: what is the trigger?
Topics: Drug Eruptions; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nu | 1999 |
Emergence of unusual cytogenetic abnormalities under interferon-alpha therapy in patients with chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Chromosome Aberrations; Chromo | 1999 |
[Alpha-interferons in the treatment of patients with chronic myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busu | 1999 |
A cytogenetic and fluorescence in situ hybridization evaluation of interferon-alpha in the treatment of chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aneuploidy; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Bone Marr | 1999 |
Long-term response in accelerated-phase chronic myelogenous leukemia with protracted splenic irradiation and alpha-interferon.
Topics: Adult; Antineoplastic Agents; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, | 1999 |
Hydroxyurea-induced gangrene of the toes in a patient with chronic myelogenous leukemia.
Topics: Adult; Amputation, Surgical; Antineoplastic Agents; Female; Gangrene; Humans; Hydroxyurea; Interfero | 2000 |
Chronic myeloid leukemia with a rare variant Philadelphia translocation: t(9;22;21)(q34;q11;q22).
Topics: Chromosome Banding; Chromosomes, Human, Pair 21; Female; Fusion Proteins, bcr-abl; Humans; Hydroxyur | 2000 |
Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia.
Topics: Aged; Antineoplastic Agents; beta 2-Microglobulin; Biomarkers, Tumor; Cytarabine; Disease-Free Survi | 2000 |
A note on nucleoli in granulocytic precursors of the granulopoietic proliferating compartment in patients suffering from the chronic phase of chronic myeloid leukemia treated with two different drugs with different mode of action.
Topics: Cell Nucleolus; Granulocytes; Hematopoiesis; Hematopoietic Stem Cells; Humans; Hydroxyurea; Interfer | 1999 |
Hydroxyurea-induced cutaneous ulceration in older patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Foot Ulcer; Humans; Hydroxyurea; Leukemia, M | 2000 |
Hydroxyurea-induced leg ulcers treated with Apligraf.
Topics: Aged; Antineoplastic Agents; Collagen; Female; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous | 2000 |
[beta-thalassemia minor diagnosed in a patient with chronic myelogenous leukemia during hydroxyurea therapy].
Topics: Antineoplastic Agents; beta-Thalassemia; Globins; Hemoglobins; Humans; Hydroxyurea; Leukemia, Myelog | 2000 |
Chronic myelogenous leukemia in chronic phase for 16 years: ongoing hematological remission and late minor cytogenetic response under minimal interferon maintenance therapy.
Topics: Adult; Antineoplastic Agents; Busulfan; Chronic Disease; Cytogenetics; Female; Humans; Hydroxyurea; | 1999 |
Use of hydroxyurea and alpha-interferon in chronic myeloid leukemia during pregnancy: a case report.
Topics: Adult; Antineoplastic Agents; Female; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, | 2000 |
[The analysis of failures in the treatment of children with chronic myelocytic leukemia in the studies of Polish pediatric leukemia/ lymphoma group].
Topics: Adolescent; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; C | 1998 |
Pure red cell aplasia in a patient with chronic granulocytic leukaemia treated with interferon-alpha.
Topics: Aged; Anemia; Blood Transfusion; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 22; Huma | 2000 |
Serum vitamin E levels in patients of chronic myeloid leukaemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Case-Control Studies; Hum | 1999 |
An accelerrated-phase CML patient with e19a2 junction of BCR/ABL gene - the first case of transplanted CML with micro bcr.
Topics: Abortion, Therapeutic; Adult; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Diseas | 2000 |
Type I and type II T cell profiles in chronic myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Female; Humans; Hydroxyurea; Immunity, Cel | 2000 |
Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Bone Marrow; Busulfan; Disease Pro | 2000 |
Therapy-related changes of CD20+ and CD45RO+ lymphocyte subsets in chronic myeloid leukemia (CML): an immunohistochemical and morphometric study on sequential trephine biopsies of the bone marrow.
Topics: Adult; Antigens, CD20; Antineoplastic Agents; Biopsy; Bone Marrow; Busulfan; Cohort Studies; Drug Th | 2000 |
Hydroxyurea treatment for chronic myeloid leukemia during pregnancy.
Topics: Adult; Antineoplastic Agents; Female; Humans; Hydroxyurea; Infant, Newborn; Leukemia, Myelogenous, C | 2000 |
Changing patterns of histological subgroups during therapy of Ph1+ chronic myelogenous leukaemia.
Topics: Adult; Antineoplastic Agents; Bone Marrow; Busulfan; Granulocytes; Humans; Hydroxyurea; Interferon a | 2000 |
[Hematologic and cytogenetic response to treatment in patients with chronic myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; | 2000 |
Hydroxyurea-induced leg ulcers.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, BCR-ABL Posit | 2000 |
Meisoindigo for the treatment of chronic myelogenous leukaemia.
Topics: Drug Therapy, Combination; Drugs, Chinese Herbal; Humans; Hydroxyurea; Indoles; Leukemia, Myelogenou | 2000 |
BCR/ABL-negative clonogenic hematopoietic cells do not accumulate in the plastic-adherent fraction of peripheral blood mononuclear cells from patients with chronic myeloid leukemia in stable chronic phase.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Bone Marrow Purging; Cell Adhesion; Cell Separ | 2000 |
Interferon-alpha-treated patients with chronic myelogenous leukemia show BCR/ABL-positive peripheral blood progenitor cells surviving long-term culture.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; | 2000 |
Hydroxyurea-induced fever in a patient with chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Fever; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; | 2000 |
[Anhidrosis during long-term hydroxyurea therapy in a patient with chronic myelogenous leukemia].
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Hypohidrosis; Leukemia, Myelogenous, Chronic, BCR-ABL Po | 2000 |
Hydroxyurea induced leg ulcers.
Topics: Adult; Antineoplastic Agents; Fatal Outcome; Female; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelo | 2000 |
A unique, complex variant philadelphia chromosome translocation in a patient with typical chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Chromosome Painting; Humans; Hydroxyurea; Karyotyping; Leukemia, Myelo | 2001 |
Prognostic impact of bone marrow erythropoietic precursor cells and myelofibrosis at diagnosis of Ph1+ chronic myelogenous leukaemia--a multicentre study on 495 patients.
Topics: Adult; Bone Marrow; Busulfan; Erythroid Precursor Cells; Female; Humans; Hydroxyurea; Immunohistoche | 2001 |
In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Drug Int | 2001 |
Thrombocytosis--report of a case.
Topics: Aged; Antineoplastic Agents; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Po | 2000 |
Localised chronic eyedlid disease resulting from long term hydroxyurea therapy.
Topics: Antineoplastic Agents; Blepharitis; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Pos | 2001 |
Limbal stem cell deficiency arising from systemic chemotherapy.
Topics: Aged; Antineoplastic Agents; Corneal Transplantation; Humans; Hydroxyurea; Keratitis; Leukemia, Myel | 2001 |
Two siblings with chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Humans; Hydroxyurea; Interferon-alpha; | 2000 |
BCR-ABL positive essential thrombocythaemia: a variant of chronic myelogerous leukaemia or a distinct clinical entity: a special case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Marrow; Diagnosis, Diffe | 2000 |
Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission.
Topics: Adult; Aged; Case-Control Studies; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD56 Antigen; CD8-Posi | 2001 |
Hydroxyurea and periodicity in myeloproliferative disease.
Topics: Adult; Aged; Antineoplastic Agents; Blood Cell Count; Busulfan; Female; Hemoglobins; Humans; Hydroxy | 2001 |
Behcet's disease in a patient with chronic myelogenous leukemia under hydroxyurea treatment: a case report and review of the literature.
Topics: Antineoplastic Agents; Behcet Syndrome; Fatal Outcome; Female; HLA-B Antigens; Humans; Hydroxyurea; | 2001 |
Mini-ice protocol is better than high-dose hydroxyurea to mobilize Ph-negative cells in earlier phases of chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Hydroxyurea; Ifosfamid | 2001 |
Near haploid blast phase in a chronic myeloid leukemia detected by fluorescence in situ hybridization using a BCR-ABL probe.
Topics: Antineoplastic Agents; Blast Crisis; Genes, abl; Haploidy; Humans; Hydroxyurea; In Situ Hybridizatio | 2001 |
Leukemic synovitis as a presentation of myelomonocytic blast crisis of chronic myeloid leukemia.
Topics: Adult; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Blast Crisis; Combined M | 2001 |
[Cytogenetic analysis and bcr/abl mRNA detection in chronic myeloid leukemia].
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Female; Fusion Proteins, bcr- | 1999 |
Chronic myelogenous leukemia following kidney transplantation in a pediatric patient.
Topics: Adolescent; Antineoplastic Agents; Azathioprine; Human Growth Hormone; Humans; Hydroxyurea; Immunosu | 2001 |
Autologous reconstitution combined with durable leukemic remission after allogeneic BMT for CML: absence of persistence of a donor-derived T cell effector population.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Bone Marrow T | 2001 |
[Hydroxyurea-induced leg ulcers in patients with chronic myeloproliferative disorders].
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Female; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelo | 2001 |
Multiple herpes simplex virus infections with various resistance patterns in a matched unrelated donor transplant recipient.
Topics: Acyclovir; Antineoplastic Agents, Alkylating; Antiviral Agents; Bone Marrow Transplantation; Cidofov | 2001 |
Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Child; Combined Modality Therapy; Fe | 2001 |
On the use of Cox regression in the presence of an irregularly observed time-dependent covariate.
Topics: Analysis of Variance; Antineoplastic Agents; Belgium; Computer Simulation; Humans; Hydroxyurea; Inte | 2001 |
Therapy-related changes of CD34+ progenitor cells in chronic myeloid leukemia: a morphometric study on sequential trephine biopsies.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Cells; Case-Cont | 2001 |
Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Component | 2002 |
Coexistence of independent myelodysplastic and Philadelphia chromosome positive clones in a patient treated with hydroxyurea.
Topics: Aged; Antineoplastic Agents; Blast Crisis; Cell Differentiation; Chronic Disease; Female; Humans; Hy | 2002 |
Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide.
Topics: Adult; Antisickling Agents; beta-Thalassemia; Drug Therapy, Combination; Humans; Hydroxyurea; Leukem | 2002 |
[Influence of chemotherapeutants and cytokines on growth and transgene expression of bone marrow cells from MT/p210(bcr-abl) transgenic mice].
Topics: Animals; Antigens, Polyomavirus Transforming; Antineoplastic Combined Chemotherapy Protocols; Bone M | 1999 |
[Results of treatment of children with chronic myelogenous leukaemia (CML) obtained by the Polish Paediatric Leukaemia/Lymphoma Study Group].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; C | 2000 |
Successful treatment for leg ulcers due to hydroxyurea in a patient with chronic myelogenous leukaemia.
Topics: Antineoplastic Agents; Debridement; Drug Combinations; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Mye | 2002 |
Successful treatment of chronic myeloid leukemia during pregnancy with hydroxyurea.
Topics: Adult; Antineoplastic Agents; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL P | 2002 |
A case of drug-induced colitis complicating the administration of hydroxycarbamide.
Topics: Antineoplastic Agents; Colitis; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positiv | 2002 |
Phenylarsine oxide augments tyrosine phosphorylation in hematopoietic cells.
Topics: Aged; Animals; Arsenicals; Blood Platelets; Busulfan; Cell Line; Dithiothreitol; Gene Rearrangement; | 1992 |
Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modalit | 1992 |
[Therapy of chronic myelogenous leukemia].
Topics: Alkylating Agents; Animals; Bone Marrow Transplantation; Combined Modality Therapy; Humans; Hydroxyu | 1992 |
[Hydrea, an effective drug for chronic myelogenous leukemia].
Topics: Administration, Oral; Animals; Drug Administration Schedule; Humans; Hydroxyurea; Leukemia L1210; Le | 1992 |
Pregnancy during myelosuppressive treatment for chronic myelogenous leukemia.
Topics: Adult; Female; Humans; Hydroxyurea; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Posit | 1992 |
Multiple skin tumors in long-term treatment with hydroxyurea.
Topics: Aged; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Skin Neoplasms | 1992 |
Hydroxyurea and pregnancy.
Topics: Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pregnancy; Pregnancy | 1992 |
Prognosis and therapy in chronic myeloid leukaemia.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Humans; Hydroxyurea; Leukemia, Myelogenous | 1992 |
A phase II pilot trial of high-dose hydroxyurea in chronic myelogenous leukemia.
Topics: Administration, Oral; Adult; Bone Marrow; Drug Evaluation; Female; Humans; Hydroxyurea; Leukemia, My | 1992 |
Several new approaches to improvement of alpha interferon therapy in chronic myelogenous leukaemia.
Topics: Animals; Combined Modality Therapy; Genetic Therapy; Humans; Hydroxyurea; Interferon-alpha; Leukemia | 1991 |
Effect of hydroxyurea on blood viscosity in chronic myelogenous leukemia with hyperleukocytosis.
Topics: Adolescent; Adult; Blood Viscosity; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR | 1991 |
Ulcerative lichen planus-like dermatitis associated with hydroxyurea.
Topics: Drug Eruptions; Female; Hand Dermatoses; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-AB | 1991 |
Multiple pigmented nail bands during hydroxyurea therapy: an uncommon finding.
Topics: Aged; Female; Fingers; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nail D | 1991 |
Successful stimulation of autologous bone marrow recovery by GM-CSF and IL-3 after an unrelated donor BMT for juvenile CML complicated by graft failure.
Topics: Bone Marrow; Bone Marrow Transplantation; Cell Survival; Combined Modality Therapy; Drug Synergism; | 1991 |
Leukocyte interferon in the treatment of chronic myelogenous leukemia in second chronic phase.
Topics: Adult; Bone Marrow; Follow-Up Studies; Hemoglobins; Humans; Hydroxyurea; Interferon Type I; Leukemia | 1991 |
First case in Tunisia of PH1 positive chronic myelogenous leukemia in a 3 year old child.
Topics: Age Factors; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Female; | 1991 |
The role of the MDR-1/P-170 mechanism in the development of multidrug resistance in chronic myeloid leukemia.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Busulfan; Drug Resistance; Ge | 1990 |
Cyclic oscillations of leucocyte counts in chronic myeloid leukaemia.
Topics: Busulfan; Hemoglobins; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukoc | 1991 |
Cytogenetics and molecular analysis in chronic myelogenous leukemia patients treated by interferon and chemotherapy.
Topics: Adult; Combined Modality Therapy; Cytarabine; Female; Humans; Hydroxyurea; Interferon Type I; Leukem | 1990 |
Hydroxyurea-induced acute alveolitis in a patient with chronic myeloid leukaemia.
Topics: Aged; Alveolitis, Extrinsic Allergic; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL P | 1990 |
The combined use of busulfan and hydroxyurea in the treatment of chronic myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Humans; Hydroxyurea; Leukemi | 1990 |
Postoperative pulmonary leukostasis.
Topics: Aged; Allopurinol; Cytarabine; Drug Therapy, Combination; Humans; Hydroxyurea; Leukemia, Myelogenous | 1990 |
Current treatment of chronic myelogenous leukemia.
Topics: Blast Crisis; Bone Marrow Transplantation; Busulfan; Humans; Hydroxyurea; Interferons; Leukemia, Mye | 1989 |
Therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Female; Humans; Hydroxyur | 1989 |
[Myeloid crisis of chronic myelogenous leukemia showing dramatic response to mithramycin and hydroxyurea combination].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Female; Humans; Hydroxyurea; Le | 1989 |
Interferon alpha induced and maintained complete remission in chronic granulocytic leukemia in relapse after bone marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Combined Modality Therapy; Graft Survival; Hematopoiesis; Humans | 1989 |
Establishment of donor hematopoiesis after hydroxyurea-induced aplasia following allograft failure in a patient with monosomy 7 variant of childhood chronic myelogenous leukemia.
Topics: Bone Marrow; Bone Marrow Transplantation; Chimera; Chromosome Deletion; Chromosomes, Human, Pair 7; | 1989 |
1,10-phenanthroline potentiates cytotoxicity of hydroxyurea in human chronic myeloid leukemia cells.
Topics: DNA; Drug Synergism; Humans; Hydroxyurea; Iron; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Le | 1989 |
A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Humans; Hydroxyurea; Interferon alp | 1989 |
Combined therapy interferon and chemotherapy in chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Co | 1989 |